<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Endocrinology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30873120</article-id>
<article-id pub-id-type="pmc">6401612</article-id>
<article-id pub-id-type="doi">10.3389/fendo.2019.00111</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Genetic and Molecular Mechanisms of Congenital Hyperinsulinism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Galcheva</surname>
<given-names>Sonya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/679835/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Demirbilek</surname>
<given-names>Hüseyin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/509910/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Khawaga</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/624578/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hussain</surname>
<given-names>Khalid</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/155756/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Paediatrics, University Hospital St. Marina, Varna Medical University</institution>, <addr-line>Varna</addr-line>, <country>Bulgaria</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Paediatric Endocrinology, Hacettepe University Faculty of Medicine</institution>, <addr-line>Ankara</addr-line>, <country>Turkey</country></aff>
<aff id="aff3"><sup>3</sup><institution>Division of Endocrinology, Department of Paediatric Medicine, Sidra Medicine</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Tsutomu Ogata, Hamamatsu University School of Medicine, Japan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Tohru Yorifuji, Osaka City General Hospital, Japan; Tatsuhiko Urakami, Nihon University, Japan</p>
</fn>
<corresp id="c001">*Correspondence: Khalid Hussain <email>khussain@sidra.org</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Pediatric Endocrinology, a section of the journal Frontiers in Endocrinology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>111</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Galcheva, Demirbilek, Al-Khawaga and Hussain.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Galcheva, Demirbilek, Al-Khawaga and Hussain</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Congenital hyperinsulinism (CHI) is a heterogenous and complex disorder in which the unregulated insulin secretion from pancreatic beta-cells leads to hyperinsulinaemic hypoglycaemia. The severity of hypoglycaemia varies depending on the underlying molecular mechanism and genetic defects. The genetic and molecular causes of CHI include defects in pivotal pathways regulating the secretion of insulin from the beta-cell. Broadly these genetic defects leading to unregulated insulin secretion can be grouped into four main categories. The first group consists of defects in the pancreatic K<sub>ATP</sub> channel genes (<italic>ABCC8</italic> and <italic>KCNJ11</italic>). The second and third categories of conditions are enzymatic defects (such as GDH, GCK, HADH) and defects in transcription factors (for example HNF1α, HNF4α) leading to changes in nutrient flux into metabolic pathways which converge on insulin secretion. Lastly, a large number of genetic syndromes are now linked to hyperinsulinaemic hypoglycaemia. As the molecular and genetic basis of CHI has expanded over the last few years, this review aims to provide an up-to-date knowledge on the genetic causes of CHI.</p>
</abstract>
<kwd-group>
<kwd>hyperinsulinism</kwd>
<kwd>hypoglycaemia</kwd>
<kwd>molecular mechanisms</kwd>
<kwd>genetics</kwd>
<kwd>mutation</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="190"></ref-count>
<page-count count="18"></page-count>
<word-count count="14174"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Congenital hyperinsulinism (CHI) is a heterogeneous and complex biochemical disorder which is characterized by the dysregulated release of insulin from pancreatic β-cell (<xref ref-type="bibr" rid="B1">1</xref>). In normal physiological state, the secretion of insulin is tightly coupled to glucose metabolism within the β-cell so that the insulin release is regulated to keep the plasma glucose concentration around 3.5–5.5 mmol/L. However, in CHI the secretion of insulin becomes unrelated to glucose metabolism, so that there is inappropriate insulin release for the plasma glucose level (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>The genetic and molecular cause of CHI includes defects in key genes regulating insulin secretion from the pancreatic β-cell. Molecular defects in previously described genes (<italic>ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, PGM1</italic>, and <italic>PMM2)</italic> have been reported (<xref ref-type="bibr" rid="B3">3</xref>). However, recent studies have linked the role of other genes (<italic>CACNA1D, FOXA2</italic>) to hyperinsulinaemic hypoglycaemia (HH) but in some of these cases the underlying molecular mechanisms are still not fully elucidated (<xref ref-type="table" rid="T1">Table 1</xref>). Understanding the molecular mechanisms of CHI due to these genetic abnormalities has provided unique insight into the normal physiological mechanisms which regulate the insulin release.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Monogenic causes of CHI.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Protein</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Function</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Chromosome</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Diazoxide responsive</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Focal vs. diffuse</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mode of inheritance</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pathogenicity</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="8" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CHI DUE TO DEFECTS IN CHANNEL AND TRANSPORTER PROTEINS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ABCC8 KCNJ11</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">SUR1 Kir6.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">K<sub>ATP</sub> channel; regulation of channel gating</td>
<td align="left" colspan="1" rowspan="1" valign="top">11p15.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">±<break></break>No<break></break>No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse Focal Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant Monoallelic recessive (Paternally inherited) Biallelic recessive</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CACNA1D</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">CACNA1D</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encodes L-type voltage-gated calcium channels that play a pivotal role in the regulation of insulin secretion</td>
<td align="left" colspan="1" rowspan="1" valign="top">3p21.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sporadic</td>
<td align="left" colspan="1" rowspan="1" valign="top">±</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SLC16A1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">MCT1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mediates the transport of lactate and pyruvate across cell membranes</td>
<td align="left" colspan="1" rowspan="1" valign="top">1p13.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">±</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CHI DUE TO ABNORMALITIES IN METABOLIC PATHWAYS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GLUD 1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GDH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Central role in nitrogen metabolism, catalyses the oxidative deamination of 1-glutamate to 2-oxoglutarate</td>
<td align="left" colspan="1" rowspan="1" valign="top">10q23.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GCK</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GCK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Important regulatory role in glucose metabolism</td>
<td align="left" colspan="1" rowspan="1" valign="top">7p15-p13</td>
<td align="left" colspan="1" rowspan="1" valign="top">±</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>HADH</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">HADH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Catalyzes the reversible dehydrogenation of 3-hydroxyacyl-CoAs</td>
<td align="left" colspan="1" rowspan="1" valign="top">4q22-q26</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biallelic recessive</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>UCP2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">UCP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Control of pathway involved in dissipation of the proton electrochemical gradient across the inner mitochondrial membrane</td>
<td align="left" colspan="1" rowspan="1" valign="top">11q13.4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">±</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>HK1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">HKI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Catalyzes the first step in glucose metabolism, using ATP for the phosphorylation of glucose to glucose-6-phosphate</td>
<td align="left" colspan="1" rowspan="1" valign="top">10q22.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic (somatic) dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PGM1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">PGM1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Catalyzes the transfer of phosphate between the 1 and 6 positions of glucose</td>
<td align="left" colspan="1" rowspan="1" valign="top">1p31.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">No</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biallelic recessive</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PMM2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">PMM2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Encodes phosphomannomutase, an enzyme essential for the synthesis of GDP-mannose</td>
<td align="left" colspan="1" rowspan="1" valign="top">16p13.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Biallelic recessive</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CHI DUE TO DEFECTS IN TRANSCRIPTION FACTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>HNF4A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">HNF4α</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates genes largely involved in the hepatic gluconeogenic program and lipid metabolism</td>
<td align="left" colspan="1" rowspan="1" valign="top">20q13.12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>HNF1A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">HNF1α</td>
<td align="left" colspan="1" rowspan="1" valign="top">Binds to a sequence required for hepatocyte-specific transcription of the genes for the alpha and beta chains of fibrinogen and alpha-1-antitrypsin</td>
<td align="left" colspan="1" rowspan="1" valign="top">12q24.31</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monoallelic dominant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>FOXA2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">HNF 3β</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription factor required for notochord formation during embryonic development involved in endoderm-derived organ system</td>
<td align="left" colspan="1" rowspan="1" valign="top">20p11.21</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sporadic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>SUR1, sulfonylurea receptor 1; Kir6.2, inwardly rectifying potassium channel 6.2; GDH, glutamate dehydrogenase; GCK, glucokinase; HADH, 3-hydroxyacyl-CoA dehydrogenase; MCT1, monocarboxylate transporter 1; UCP2, uncoupling protein 2; HNF1A, hepatocyte nuclear factor 1A; HNF3β, hepatic nuclear factor 3β; HNF4A, hepatocyte nuclear factor 4A; HK1, hexokinase 1; PGM1, phosphoglucomutase 1; PMM2, phosphomannomutase 2; CACNA1D, Calcium voltage-gated channel subunit α1 D; FOXA2, forkhead box protein A2</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Broadly, these genetic defects leading to unregulated insulin secretion can be grouped into four main categories. The first group consists of defects in genes encoding the pancreatic K<sub>ATP</sub> channels (<italic>ABCC8</italic> and <italic>KCNJ11</italic>) and other channel/transporter proteins (<italic>KCNQ1, CACNA1D, SLC16A1</italic>) (<xref ref-type="fig" rid="F1">Figure 1</xref>). Pancreatic K<sub>ATP</sub> channels have a critical role in the regulation of insulin release and defects in their encoding genes cause the most prevalent and severe forms of CHI (<xref ref-type="bibr" rid="B4">4</xref>). The second and third categories of conditions are enzymatic gene defects (<italic>GLUD1, GCK, HADH, UCP2, HK1, PMM2, PGM1</italic>) and defects in genes encoding the transcription factors (<italic>HNF1A, HNF4A, FOXA2</italic>) leading to changes in nutrient flux into metabolic pathways which converge on insulin secretion (<xref ref-type="bibr" rid="B5">5</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). The β-cell insulin release is coupled to the metabolic signals and so any perturbation in these pathways will ultimately result in inappropriate insulin secretion. Lastly, there are a large number of syndromic conditions (like Beckwith-Weidemann syndrome) which feature HH as a part of the syndrome while the underlying molecular mechanism leading to unregulated insulin secretion has yet to be clarified in most of the syndromes (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Channel and transporter proteins involved in the process of insulin secretion from pancreatic β-cells. ADP, adenosine diphosphate; ATP, adenosine triphosphate; Ca<sup>2+</sup>, calcium ions; cAMP, cyclic adenosine monophosphate; G6P, glucose 6-phosphate; GLP1, glucagon like peptide 1; GLUT 2, glucose transporter 2; K<sup>+</sup>, potassium; Kir6.2, inward rectifier potassium channel 6.2; MCT1, monocarboxylate transporter 1; Pyr, pyruvate; SUR1, sulfonylurea receptor 1; TCA, tricarboxylic acid.</p>
</caption>
<graphic xlink:href="fendo-10-00111-g0001"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Metabolic pathways and transcription factors related to the development of CHI. ADP, adenosine diphosphate; ATP, adenosine triphosphate; αKG, alpha ketoglutarate; Ca<sup>2+</sup>, calcium ions; ER, endoplasmic reticulum; G1P, gluscose-1-phosphate; G6P, glucose 6-phosphate; GABA, γ-aminobutyric acid; GAD, glutamate decarboxylase enzyme; GDH, glutamate dehydrogenase; GLUT, glucose transporter; HADH, hydroxyacyl-CoA dehydrogenase; HNF1α, hepatocyte nuclear factor 1α; HNF4α, hepatocyte nuclear factor 4α; K<sup>+</sup>, potassium; NH3, ammonia; PGM1, phosphoglucomutase 1; PMM2, phosphomannomutase 2; Pyr, pyruvate; TCA, tricarboxylic acid; UCP2, mitochondrial uncoupling protein 2.</p>
</caption>
<graphic xlink:href="fendo-10-00111-g0002"></graphic>
</fig>
<p>In this article, we review the state of the art knowledge on the genetic and molecular basis of all the different types of CHI and discuss a possible new classification of the molecular basis of CHI.</p>
<sec>
<title>β-Cell Glucose Sensing and the Role of K<sub>ATP</sub> Channels in Insulin Release</title>
<p>The rise of plasma glucose levels after feeding triggers insulin release from the β-cells. The glucose enters the β-cells via the facilitated diffusion driven by the glucose transporter 2 (GLUT2), where it undergoes glycolytic phosphorylation mediated by the enzyme glucokinase (GCK, a hexokinase) and converts to glucose-6-phosphate (G6P). Recently, it has been shown that other hexokinases, particularly HK1, are also expressed in the neonatal β-cells but the gene expression is downregulated after birth during the maturation of the β-cells (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>GCK is a glucose sensor linking the extracellular concentration of glucose and its metabolism in the β-cells (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The rise of the plasma glucose leads to an enhanced GCK activity producing energy rich compounds (ATP) and results in an increase in the cytoplasmic ATP:ADP ratio. The β-cell insulin release is mostly regulated by the ATP-sensitive potassium (K<sub>ATP</sub>) channel located in the membrane of the pancreatic β-cells (<xref ref-type="bibr" rid="B11">11</xref>). These channels have a crucial role in the glucose homeostasis as they link its metabolism to the membrane electrical excitability with a consequent β-cells secretion of insulin (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>The β-cell K<sub>ATP</sub> channel is a large hetero-octamer with a 4:4 stoichiometry, composed of 4 pore-forming inwardly-rectifying K<sup>+</sup> channel subunits (Kir6.2) and 4 high-affinity regulatory SUR1 subunits. The Kir6.2 subunit, a “weak” inward rectifier (<xref ref-type="bibr" rid="B14">14</xref>), contains two putative transmembrane domains (TMD1 and TMD2), bound by an extracellular loop (H5), and cytosolic -NH2 and -COOH terminal domains containing ~70 and ~220 amino acid residues, respectively.</p>
<p>The Kir6.2 subunit of K<sub>ATP</sub> channel affects the biophysical characteristics of the channel complex such as K<sup>+</sup> selectivity, rectification, activation by acyl-CoAs and inhibition by ATP (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The SUR1 subunit provides the channels with a susceptibility to the stimulatory effects of MgADP and confers on the channels a responsiveness to pharmacological activators (diazoxide) and inhibitiors (sulfonylureas) (<xref ref-type="bibr" rid="B16">16</xref>). It promotes ATP hydrolysis without directly transporting the substrates and regulates the Kir6.2 activity in the K<sub>ATP</sub> channel complex.</p>
<p>Only fully-assembled channel complexes which are properly transported to the surface of the cell membrane (trafficking) can operate correctly (<xref ref-type="bibr" rid="B17">17</xref>). Hence, only octameric K<sub>ATP</sub> channels can be expressed on the plasma membrane surface due to the masking of the endoplasmic reticulum (ER) retention signals (RKR) exposed in partially-assembled channels (<xref ref-type="bibr" rid="B18">18</xref>).</p>
<p>The key regulators of K<sub>ATP</sub> channels are the changing concentrations of intracellular nucleotides. Adenine nucleotides are capable of stimulatory interacting with Mg<sup>2+</sup>. However, the non-hydrolytic ATP binding takes advantage over K<sub>ATP</sub> channels in the lack of Mg<sup>2+</sup>. The increased cytosolic ATP:ADP ratio inhibits the K<sub>ATP</sub> channel activity and reduces the potassium ions efflux across the plasma membrane adjusting its potential. Thus, the basal activity of the channels produce a slow depolarization until a threshold membrane potential is reached that increases the open probability of calcium channels. This process changes the physiological conformation of the potassium channels, which results in their closure, followed by chronic plasma membrane depolarization and Ca<sup>2+</sup> influx due to the voltage-gated calcium channels activation (<xref ref-type="bibr" rid="B19">19</xref>). The increased intracellular Ca<sup>2+</sup> activates specific pathways, such as protein kinases A and C, leading to impaired glucose sensing, insulin release from the storage granules and its subsequent secretion into the bloodstream (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). In a similar way, when glucose concentrations are low, the K<sub>ATP</sub> channels open, causing membrane hyperpolarization and subsequently inhibited release of insulin (<xref ref-type="bibr" rid="B22">22</xref>).</p>
</sec>
</sec>
<sec id="s2">
<title>CHI Due to Defects in Channel and Transporter Proteins</title>
<sec>
<title>Pancreatic β-Cell K<sub>ATP</sub> Channel Defects (<italic>ABCC8</italic> and <italic>KCNJ11</italic> Gene Mutations) and CHI</title>
<p>Mutations in <italic>ABCC8</italic> and <italic>KCNJ11</italic> genes account for the main genetic causes of CHI, characterized by defective pancreatic β-cell K<sub>ATP</sub> channel subunits (SUR1 and Kir6.2, respectively). Both genes are mapped on the same chromosome (11p15.1), being divided by a small part of DNA (4.5 kb) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B23">23</xref>). The <italic>ABCC8</italic> gene is a large gene spanning more than 100 kb of DNA, divided in 39 exons (<xref ref-type="bibr" rid="B20">20</xref>). The <italic>KCNJ11</italic> gene consists only 1 exon encoding a protein (Kir6.2) with a molecular weight of about 43kDa (<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p><italic>ABCC8</italic> or <italic>KCNJ11</italic> gene mutations have been found in ~50% of CHI patients (<xref ref-type="bibr" rid="B24">24</xref>). Based on the mutation data from the Human Gene Mutation Database (HGMD) (<ext-link ext-link-type="uri" xlink:href="http://www.hgmd.org">www.hgmd.org</ext-link>, accessed February 2018), 448 homozygous, compound heterozygous and heterozygous inactivating <italic>ABCC8</italic> mutations (<xref ref-type="bibr" rid="B25">25</xref>–<xref ref-type="bibr" rid="B28">28</xref>) and around 66 <italic>KCNJ11</italic> (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B29">29</xref>) mutations have been reported, associated with differentially expressed clinical symptoms.</p>
<p>Recessive and dominant <italic>ABCC8/KCNJ11</italic> mutations may influence the proper function of the K<sub>ATP</sub> channels either by disrupting their cell surface expression or by affecting the MgADP stimulation of their activity. As a result, in both cases, the pancreatic β-cell membrane will be continuously depolarized with uncontrolled release of insulin despite severe hypoglycaemia (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B30">30</xref>). The first type of <italic>ABCC8</italic>/<italic>KCNJ11</italic> mutations affecting the channel membrane expression impairs the SUR 1 synthesis or maturation, leading to proteins which do not reach the plasma membrane. These mutations can also cause impaired SUR1 trafficking. Since the Kir6.2 expression depends on the surface co-expression of SUR1, in these cases the Kir6.2 surface expression is also disturbed and it is missing from the membrane (<xref ref-type="bibr" rid="B4">4</xref>). The second type of mutations produce non-functional K<sub>ATP</sub> channel complexes which are insensitive to the changing MgADP concentrations and stay closed even when the glucose level drops too low (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<sec>
<title>Recessive Inactivating Mutations (Homozygous or Compound Heterozygous)</title>
<p>In <italic>ABCC8</italic> and <italic>KCNJ11</italic> genes generally cause the most severe cases of CHI, which usually do not respond to diazoxide therapy and often require a resection of the pancreas (<xref ref-type="bibr" rid="B31">31</xref>). However, some compound heterozygous mutations may cause milder hyperinsulinism which is responsive to diazoxide (<xref ref-type="bibr" rid="B32">32</xref>). The molecular basis of these recessive mutations comprises of defects in the biogenesis and turnover of K<sub>ATP</sub> channels (<xref ref-type="bibr" rid="B33">33</xref>), their abnormal exit from the ER and trafficking to the cytoplasmic membrane (<xref ref-type="bibr" rid="B34">34</xref>), and channel changes as a result of nucleotide regulation and frequency of open-state (<xref ref-type="bibr" rid="B35">35</xref>).</p>
</sec>
<sec>
<title>Recessive <italic>ABCC8/KCNJ11</italic> Mutations With Defects in Channel Biogenesis and Turnover</title>
<p>A pulse labeling study has shown that both channel subunits have long-lived species with a half-life of about 24 h, which is in accordance with the idea for a slow assembling of the K<sub>ATP</sub> channel (<xref ref-type="bibr" rid="B33">33</xref>). The Kir6.2 turnover is biphasic when the subunit is expressed individually, as about 60% having a half-life of 36 min, while the rest changes to species with a half-life of 26 h. Expressed alone SUR1 is long-lived in the ER with a half-life of more than 25 h. Being co-expressed, both channel subunits associate rapidly with an elimination of the rapid degradation of Kir6.2 (<xref ref-type="bibr" rid="B33">33</xref>). After the termination of their assembly, the channels pass to the Golgi apparatus and SURs change into the mature, completely glycosylated form.</p>
<p>For example, the F1388del and W91R mutations in <italic>ABCC8</italic> and <italic>KCNJ11</italic> genes, respectively, which are related to the development of a critical form of CHI in patients, change the subunit turnover rate (<xref ref-type="bibr" rid="B33">33</xref>). The mutant subunits connect with their relevant subunits but then dissociate and undergo a rapid degradation, affecting the K<sub>ATP</sub> channel biogenesis and turnover. Homozygous patients have no functional K<sub>ATP</sub> channels on the pancreatic β-cell surface, while heterozygous carriers possess a reduced complement of normal channels.</p>
</sec>
<sec>
<title>Recessive <italic>ABCC8/KCNJ11</italic> Mutations With Defects in Channel Trafficking</title>
<p>Channel trafficking requires the RKR signals, present in both channel subunits, to be masked during their assembly. <italic>ABCC8</italic> mutations (F1388del, L1544P) result in a defective trafficking as they influence the exit of the subunits from the ER (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Several <italic>KCNJ11</italic> mutations (Y12X, H259R, E282K) have also been described as causing a trafficking defect and truncated non-functional proteins (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>).</p>
</sec>
<sec>
<title>Recessive <italic>ABCC8/KCNJ11</italic> Mutations With Defects in Channel Regulation</title>
<p>Since the SUR1 protein operates as a conductance regulator of Kir6.2, both channel subunits are susceptible to alterations in adenosine and guanosine nucleotides. The K<sub>ATP</sub> channel regulation involves interactions of nucleotides at the subunits with an ATP-provoked Kir6.2 inhibition, which is opposed by the ADP-activation at SUR1. Some mutations in <italic>ABCC8</italic> (T1139M, R1215Q) have been reported to affect the channel conductance and lead to a loss of ADP-dependent gating, causing the ATP-induced channel inhibition (<xref ref-type="bibr" rid="B40">40</xref>). The R1420C mutation in <italic>ABCC8</italic> gene, located in NBD2 of SUR1 subunit, also reduces the channel affinity for ATP and ADP (<xref ref-type="bibr" rid="B41">41</xref>).</p>
</sec>
<sec>
<title>Dominant Inactivating <italic>ABCC8/KCNJ11</italic> Mutations</title>
<p>Show normal K<sub>ATP</sub> channel assembly and trafficking to the plasma membrane (<xref ref-type="bibr" rid="B42">42</xref>). They are uncommon and typically lead to a milder form of CHI presented at a later age, although the phenotype may vary from asymptomatic to persistent HH (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>Interestingly, in adult carriers dominant mutations can cause dominantly inherited diabetes (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). The possible mechanisms for that have been imputed to the apoptosis of the β-cell (<xref ref-type="bibr" rid="B46">46</xref>) mediated by the increased cell depolarization and subsequent Ca<sup>2+</sup> flow into the β-cell. However, the predisposition to diabetes later in life related to dominant mutations is controversial. Huopio et al. (<xref ref-type="bibr" rid="B45">45</xref>) have reported a development of impaired glucose tolerance in 75% of the mothers during pregnancy while Pinney et al. (<xref ref-type="bibr" rid="B42">42</xref>) have not seen such a positive trend toward diabetes in mutation carriers. More recently, we reported a family carrying a novel missense c.511C&gt;T (p.L171F) variant in exon 4 of <italic>ABCC8</italic> which lead to adult onset diabetes in heterozygous carriers, while a homozygous carrier developed HH at neonatal period and diabetes later in life (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>An important feature of the dominant inactivating <italic>ABCC8</italic>/<italic>KCNJ11</italic> mutations is the responsiveness of the patients to diazoxide treatment compared to those with a recessive condition (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B48">48</xref>). However, dominant forms unresponsive to medications have also been described (<xref ref-type="bibr" rid="B49">49</xref>). For example, MacMullen et al. have reported patients with medically unresponsive diffuse CHI caused by dominant <italic>ABCC8</italic> mutations, where 15 of all 17 patients have need a near-total pancreatectomy (<xref ref-type="bibr" rid="B50">50</xref>). These patients are born large for their gestational age having a similar age at clinical presentation to that of individuals with recessive mutations. The functional analyses have shown severely impaired channel responses to diazoxide and MgADP-activation; however, the channels have normal trafficking to the membrane like mutations which result in a dominant disease responsive to diazoxide therapy (<xref ref-type="bibr" rid="B50">50</xref>). It has been hypothesized that the mutations change the nucleotide hydrolysis rates affecting the diazoxide activity or they alter the coupling of MgATP-hydrolysis to the activation of the channel. It is believed that the MgATP-hydrolysis lead to desensitization to the ATP inhibition, so diazoxide and MgADP stabilize the desensitized condition of the K<sub>ATP</sub> channel (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>Most of the reported dominant medically-unresponsive variants have been located in the NBDs of the SUR1 subunit, including the same gene regions as many of the dominant medically-responsive SUR1 mutations (<xref ref-type="bibr" rid="B50">50</xref>) as well as the regions of many of the known recessive mutations (<xref ref-type="bibr" rid="B49">49</xref>). It has been shown that the involvement of Walker A and B motifs of NBD1 seems to be restricted to dominant mutations unresponsive to diazoxide treatment, whereas, the mutations affecting NBD2 are associated with both diazoxide-responsive and unresponsive hyperinsulinism (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>A dominant Kir6.2 missense mutation (F55L) causing CHI has been reported to decrease K<sub>ATP</sub> channels open probability without having an influence on the channel expression (<xref ref-type="bibr" rid="B35">35</xref>). The reduced channel activity is related to its low response to membrane phosphoinositides/long-chain acyl-CoAs (<xref ref-type="bibr" rid="B41">41</xref>). Recently, a novel phenomenon has been described in a transient CHI patient, reporting the co-existance of heterozygous <italic>ABCC8</italic> and <italic>KCNJ11</italic> gene mutations (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>The detection of a <italic>paternally inherited monoallelic K</italic><sub><italic>ATP</italic></sub>
<italic>channel mutation</italic> with a post-zygotic loss of the corresponding maternal region on chromosome 11 usually cause focal adenomatous hyperplasia accounting for 30–40% of the cases with CHI (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>). The loss of heterozygosity leading to paternal isodisomy makes the β-cells channel defects biallelic in the abnormal foci, changing the channels and causing abnormal secretion of insulin into the lesion (<xref ref-type="bibr" rid="B53">53</xref>). The subsequent disproportion in the expression of several imprinted genes involved in cell proliferation within the 11p15 region (decreased expression of the maternal tumor suppressor genes <italic>CDKN1C</italic> and <italic>H19</italic> and expression of the paternal <italic>IGF2</italic>) results in focal hyperplasia of the islet cells (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>).</p>
<p>Focal CHI due to paternally inherited monoallelic <italic>ABCC8/KCNJ11</italic> mutations is usually unresponsive to medical treatment (<xref ref-type="bibr" rid="B57">57</xref>), although a diazoxide-responsive focal form has recently been reported (<xref ref-type="bibr" rid="B58">58</xref>). In the medically unresponsive children, genetic testing should be followed by 18F-DOPA PET/CT scanning in order to determine the focal or diffuse subtypes of hyperinsulinism prior to initiating the appropriate treatment to cure the patient—targeted lesionectomy in focal forms or near-total pancreatectomy in diffuse CHI (<xref ref-type="bibr" rid="B59">59</xref>). <xref ref-type="fig" rid="F3">Figure 3</xref> outlines the genetic causes and treatment approaches to different histological subtypes of CHI.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Schematic presentation of the histological subtypes of CHI. In the diffuse CHI, there is a global hyperchromatic β-cell enlargement and hyperplasia. In the focal subtype, β-cell hyperplasia is limited to a certain region of the pancreas with a superficial or deep localization. <bold>(A)</bold> Mode of inheritance and the genetic causes of CHI in the diffuse and focal subtype, respectively; <bold>(B)</bold> Schematic illustration of diffuse, atypical and focal subtypes; <bold>(C)</bold> Management approaches to different forms of CHI.</p>
</caption>
<graphic xlink:href="fendo-10-00111-g0003"></graphic>
</fig>
<p>There are studies showing that some individuals with paternally inherited K<sub>ATP</sub> mutations may respond to diazoxide or resolve spontaneously (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B60">60</xref>). They are likely to have dominant acting CHI, exerting the effect of the heterozygous <italic>ABCC8/KCNJ11</italic> mutations by a dominant-negative mechanism leading to diffuse CHI (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). Possible mechanisms of how heterozygous mutations can cause a diffuse disease could be a post-zygotic mutation affecting the other allele (“second hit” in the pancreas) or inability to identify a channel mutation inherited from the mother due to localization in a non-coding region of the genes (<xref ref-type="bibr" rid="B62">62</xref>).</p>
<p>A novel genetic mechanism of some atypical diffuse forms of CHI has been described in an individual with a nonsense heterozygous <italic>ABCC8</italic> mutation (Q54X) due to mosaic segmental paternal isodisomy (<xref ref-type="bibr" rid="B63">63</xref>). The absence of focal disease in this case has been explicated by the absence of uniparental disomy at the 11p15.5 region.</p>
</sec>
</sec>
<sec>
<title>Mutations in <italic>KCNQ1</italic> and HH</title>
<p>It has been reported that the pore-forming region of the α-subunit of a voltage-gated potassium channel (Kv7.1) is encoded by the <italic>KCNQ1</italic> gene. The channel, located in the heart, inner ear, stomach, colon and pancreatic β-cells, is crucial for ion homeostasis in the tissues. The gene mutations are associated with cardiac arrhythmias (i.e., the hereditary long QT syndrome (LQTS), deafness and defects of the gastrointestinal system (<xref ref-type="bibr" rid="B64">64</xref>). Recently, it has been reported the presence of HH in individuals with LQTS caused by <italic>KCNQ1</italic> mutations (<xref ref-type="bibr" rid="B65">65</xref>). These patients experience increased release of insulin during an oral glucose tolerance test with hypoglycaemic episodes following the prolonged test. Although the Kv7.1 role in the glucose metabolism is not fully ellucidated, data suggest that this channel may regulate insulin secretion by controlling the process of repolarization of plasma membrane.</p>
</sec>
<sec>
<title>Mutations in <italic>CACNA1D</italic> and HH</title>
<p>Calcium Voltage-Gated Channel Subunit Alpha1 D (<italic>CACNA1D)</italic> encodes an L-type voltage-sensitive Ca<sup>2+</sup> channel that affects the regulation of insulin release from the β-cells (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>). Activating germline mutations in <italic>CACNA1D</italic> gene have previously been found in patients with primary hyperaldosteronism, neuromuscular abnormalities, and transient diazoxide-responsive hypoglycaemia (<xref ref-type="bibr" rid="B68">68</xref>). In a recent study the same <italic>CACNA1D</italic> gene mutation has been shown in a patient with HH, cardiac defects and severe hypotonia (<xref ref-type="bibr" rid="B69">69</xref>). This mutation causes an activation of the L-type Ca<sup>2+</sup> channel and leading the channel remain open at a lower membrane potential, thereby results in dysregulated insulin secretion (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>). Taking into consideration the role of these channels in the process of β-cell insulin release, the heterozygous c.1208G&gt;A (p.G403D) mutation detected in present and previously published cases, suggested <italic>CACNA1D</italic> as one of the candidate genes for the underlying molecular genetic etiology of CHI. In addition, although the reported patient was diazoxide-responsive, considering the insulin secretion physiology from the β-cells and the role of Ca<sup>2+</sup> influx from the voltage gated Ca<sup>2+</sup> channels, it was suggested that calcium channel blockers would be a more effective option for the medical management of these patients (<xref ref-type="bibr" rid="B69">69</xref>). However, the underlying molecular mechanism leading to CHI is still not clear and requires further investigations and more experiences on HH patients with mutations of this gene.</p>
</sec>
<sec>
<title>Mutations in <italic>SLC16A1</italic> Gene and CHI</title>
<p>The monocarboxylate transporter 1 (MCT1) catalyses the rapid transport of monocarboxylates (pyruvate and lactate) into the cells. It is encoded by the <italic>SLC16A1</italic> gene mapped on chromosome 1p13.2-p12. This gene consists of 5 exons and 4 introns, spanning approximately 44 kb (<xref ref-type="bibr" rid="B70">70</xref>). Under normal physiological conditions, there is a low MCT1 expression in the pancreatic β-cells, with minimized intracellular concentrations of pyruvate and lactate which do not increase the insulin release (<xref ref-type="bibr" rid="B67">67</xref>). However, dominant activating mutations in the <italic>SLC16A1</italic> gene promoter cause an enhanced MCT1 expression in the pancreatic islets, followed by an increased uptake of pyruvate and its metabolism in the Krebs cycle, with a subsequently increased production of ATP and insulin exocytosis (<xref ref-type="bibr" rid="B71">71</xref>).</p>
<p>The activating <italic>SLC16A1</italic> mutations cause CHI known as exercise-induced hyperinsulinism. The condition is characterized by hypoglycaemic episodes which usually occur within 30–45 min. after strenuous activity, in response to the accumulation of pyruvate and lactate, acting as insulin secretagogues. Sometimes diazoxide therapy may not prevent hypoglycaemia, so avoiding intense physical activity and carbohydrate intake during or after the exercise may require as a part of the treatment (<xref ref-type="bibr" rid="B72">72</xref>).</p>
<p>Although previously reported mutations have been limited to the <italic>SLC16A1</italic> promoter region, recently the first intragenic heterozygous mutation (c.556C&gt;G, p.L186V) has been described in a child with CHI (<xref ref-type="bibr" rid="B73">73</xref>). This mutation has been found to be “probably damaging” leading to gene overexpression or baseline low expression of a mutant transport protein, followed by its enhanced transport into the pancreatic cells with subsequent increase in insulin release (<xref ref-type="bibr" rid="B73">73</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>CHI Due to Abnormalities in Metabolic Pathways</title>
<p>Other known genetic causes of CHI involved in β-cell dysregulation and abnormal insulin secretion have been identified. These involve defects in metabolic pathways converging on insulin secretory mechanisms.</p>
<sec>
<title>Mutations in <italic>GLUD1</italic> Gene and CHI (Hyperinsulinism/Hyperammonaemia Syndrome)</title>
<p>The <italic>GLUD1</italic> gene is mapped on chromosome 10q23.3. The gene consists of 13 exons and encodes the homohexameric enzyme glutamate dehydrogenase (GDH) (<xref ref-type="bibr" rid="B74">74</xref>), present in the mitochondrial matrix and mainly expressed in the liver, kidneys, brain and pancreas (<xref ref-type="bibr" rid="B75">75</xref>). GDH catalyses the reversible oxidation of the amino acid L-glutamate to α-ketoglutarate (αKG) and ammonia in the liver and kidney requiring NAD<sup>+</sup> or NADP<sup>+</sup> as a co-enzyme. In the pancreatic β-cell GDH catalyses the synthesis of αKG, a substrate for the citric acid cycle and causes an increased intracellular ATP:ADP ratio, activating the K<sub>ATP</sub> channel with subsequent cell depolarization and insulin exocytosis (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). GDH activity can be influenced by allosteric effectors working as activators (ADP and leucine) or inhibitors (GTP and ATP) (<xref ref-type="bibr" rid="B78">78</xref>).</p>
<p>Activating “<italic>de novo</italic>” or dominant missense <italic>GLUD1</italic> mutations decrease the enzyme sensitivity to the GTP allosteric inhibition and upregulate its activity in the presence of amino acid leucine, followed by increased insulin secretion (<xref ref-type="bibr" rid="B76">76</xref>). Interestingly, in a mutant GDH mouse model carrying the H454Y mutation, in addition to the loss of GTP inhibition on GDH activity, there is also an inhibition of glucagon secretion which contributes to the hypoglycaemic phenotype (<xref ref-type="bibr" rid="B79">79</xref>).</p>
<p>Activating <italic>GLUD1</italic> mutations are the second most common cause of CHI. They are identified mainly in the GTP allosteric binding site (exons 11 and 12) (<xref ref-type="bibr" rid="B80">80</xref>). Mutations have also been found in the catalytic site (exons 6 and 7), leading to a regular enzyme activity but reduced sensitivity to GTP (<xref ref-type="bibr" rid="B81">81</xref>). The exon 10 in the antenna-like region is the third domain where <italic>GLUD1</italic> mutations have been reported (<xref ref-type="bibr" rid="B82">82</xref>). The mutations cause a hyperinsulinism/hyperammonaemia syndrome (HI/HA), which is a protein/leucine-sensitive form of CHI (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). It is characterized by dysregulated insulin release and persistent elevated production of ammonia (mainly in the kidney) (<xref ref-type="bibr" rid="B85">85</xref>).</p>
<p>The HI/HA syndrome, a milder form of CHI, usually presents in late infancy and early childhood. It is characterized by a normal birth-size, fasting or postprandial protein/leucine-stimulated hypoglycaemia, with persistent but asymptomatic hyperammonaemia (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>). The latter biochemical characteristic (hyperammonaemia) is typical for the syndrome. The ammonia levels are usually 3–5 times above the normal values but the hyperammonaemia does not appear to cause symptoms of ammonia toxicity such as lethargy, headache, vomiting, coma, etc. However, some patients (mainly those with mutations in exons 6 and 7) have episodes of epilepsy, suggesting that the condition may have a direct effect on the brain (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B88">88</xref>). The suspected mechanisms for the pathogenesis of generalized epilepsy, learning disorders and developmental delay in HI/HA syndrome involve the influence of the persistent hyperammonaemia, hypoglycaemic injury of the brain and shift in the glutamate metabolism leading to decreased synthesis of inhibitory neurotransmitter γ-amino-butyric acid (GABA) in the brain due to GDH hyperactivity (<xref ref-type="bibr" rid="B88">88</xref>). However, there is no confirmative data for the association between ammonia levels and the risk for epilepsy or other neurological sequelae in these patients. Furthermore, there are individuals with <italic>GLUD1</italic> mutations who have normal ammonia concentrations, probably as a result of the mosaicism for the GDH activity(<xref ref-type="bibr" rid="B86">86</xref>).</p>
<p>Recently, a study has reported the first homozygous activating mutation of <italic>GLUD1</italic> in a neonate who has presented with severe hypoglycaemia, hyperammonaemia, and seizures soon after birth (<xref ref-type="bibr" rid="B89">89</xref>). The mutation analysis has shown a novel frameshift mutation (c.37delC) inherited from the asymptomatic mother and a <italic>de novo</italic> activating mutation (p.S445L) near the GTP binding site, leading to a more severe loss of the GTP inhibiting effects on GDH (<xref ref-type="bibr" rid="B89">89</xref>).</p>
</sec>
<sec>
<title>Mutations in Glucokinase (GCK) Gene and CHI</title>
<p>The <italic>glucokinase</italic> (<italic>GCK</italic>) gene is mapped on chromosome 7 and contains 12 exons encoding for a monomeric protein with a molecular weight of about 52 kDa. The gene has tissue specific promoters, responsible for the transcription initiation in a mutually exclusive manner in distinct tissues such as the pancreas, liver, and the brain (<xref ref-type="bibr" rid="B90">90</xref>).</p>
<p>The GCK is a hexokinase isoenzyme, that has a substantial role in the carbohydrate metabolism by acting as a glucosensor for the β-cells, regulating glucose-induced insulin release. It mediates the phosphorylation of glucose molecules on carbon 6 to produce G6P, which is the first step in glycolysis (<xref ref-type="bibr" rid="B91">91</xref>). GCK activity has a crucial role in coupling plasma glucose levels to insulin release due to its biochemical characteristics such as a low affinity for glucose, lacking inhibition by G6P and a cooperativity with respect to glucose (<xref ref-type="bibr" rid="B92">92</xref>).</p>
<p>Heterozygous <italic>GCK</italic> activating mutations cause an increased glucose affinity of the enzyme leading to hyperinsulinism. So far, 15 activating mutations associated with HH have been reported, the majority of which group at the allosteric activator domain of the enzyme (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>). The latter is the site where small-molecule activators bind, converting the GCK enzyme from its closed (active) to an open inactive state, including three intermediate stages (<xref ref-type="bibr" rid="B95">95</xref>). Natural ligands and activating mutations delay the changes in the shape of the GCK macromolecule when passing through the intermediate stages, suggesting the pivotal role of the allosteric domain in regulating the enzyme activity (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>).</p>
<p>Patients presenting with GCK-CHI have a wide spectrum of clinical presentations with a varying severity of the symptoms. Children usually have a family history of hypoglycaemia and age at clinical diagnosis ranging from birth to adulthood (<xref ref-type="bibr" rid="B98">98</xref>–<xref ref-type="bibr" rid="B101">101</xref>). Although most of the reported <italic>GCK</italic> mutations lead to CHI responsive to diazoxide therapy (<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>), some patients may need more aggressive treatment to control hypoglycaemia such as octreotide administration or surgery (<xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B102">102</xref>). For example, the Y214C mutation in the putative allosteric activator site has been found in a patient with medically-unresponsive CHI (<xref ref-type="bibr" rid="B103">103</xref>).</p>
</sec>
<sec>
<title>Mutations in HADH Gene and CHI</title>
<p>The oxidation of fatty acids is an essential process that generates ketone bodies serving as alternative metabolic substrates, used in the state of prolonged fasting. The enzyme L-3-hydroxyacyl-CoA-dehydrogenase (HADH) is a mitochondrial oxidoreductase that catalyses the third step of fatty acid β-oxidation, converting the 3-hydroxyacyl–CoA to 3-ketoacyl-CoA. The coding <italic>HADH</italic> gene is mapped on chromosome 4q22-26 and comprises 8 exons spanning approximately 49 kb (<xref ref-type="bibr" rid="B104">104</xref>). Its expression in the β-cells is controlled by different transcription factors, pivotal for the correct cellular differentiation and function (<xref ref-type="bibr" rid="B105">105</xref>).</p>
<p>Recessive inactivating <italic>HADH</italic> gene mutations have been described in CHI patients leading to a reduction in the enzyme levels (<xref ref-type="bibr" rid="B106">106</xref>–<xref ref-type="bibr" rid="B108">108</xref>). The HADH deficiency results in a loss of its inhibitory effect on GDH, causing a GDH overstimulation, followed by an increased intracellular ATP and enhanced secretion of insulin (<xref ref-type="bibr" rid="B109">109</xref>). This GDH activation is restricted mainly to the pancreatic islets and does not lead to elevated ammonia levels compared to the cases with HI/HA syndrome. Therefore, <italic>HADH</italic> mutations cause a protein/leucine-sensitive CHI due to the close link between the oxidation of fatty acids, amino acid metabolism and insulin release (<xref ref-type="bibr" rid="B110">110</xref>).</p>
<p>Patients may have heterogeneous clinical presentations which vary between mild late-onset fasting or protein/leucine-sensitive hypoglycaemia and severe hypoglycaemia soon after birth (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B111">111</xref>). Some affected individuals may also have abnormally raised metabolites of acylcarnitine such as plasma 3-hydroxybutyrylcarnitine and urinary 3-hydroxyglutaric acid, with no signs of liver or cardiac dysfunction (<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B110">110</xref>). Most children respond to diazoxide therapy, and genetic testing is suggested when patients are from consanguineous families and negative for K<sub>ATP</sub> channel mutations (<xref ref-type="bibr" rid="B112">112</xref>).</p>
</sec>
<sec>
<title>Mutations in the Mitochondrial UCP2 Gene and CHI</title>
<p>The uncoupling protein 2 (UCP2) belongs to an inner mitochondrial anion-carrier family and is encoded by the <italic>UCP2</italic> gene. It is widely expressed in many tissues, including the pancreas (<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>). UCP2 facilitates the transfer of protons across the inner membrane of mitochondria, thereby separates the mitochondrial oxidative phosphorylation from the synthesis of ATP. Since the increased intracellular ATP synthesis is the key stimulator for sensing glucose and insulin release from the pancreatic islets, the expression of UCP2 decreases the ATP synthesis and negatively regulates the glucose-induced release of insulin (<xref ref-type="bibr" rid="B114">114</xref>–<xref ref-type="bibr" rid="B116">116</xref>). Furthermore, it has been reported that the UCP2 overexpression in isolated rat β-cells downregulates the ATP synthesis and inhibits the glucose-mediatied secretion of insulin, while in UCP2 knockdown models glucose mediated insulin secretion has shown to be enhanced (<xref ref-type="bibr" rid="B117">117</xref>–<xref ref-type="bibr" rid="B119">119</xref>). Therefore, inactivating heterozygous mutations of this gene would enhance the glucose oxidation and increase intracellular ATP synthesis leading to inappropriate insulin secretion (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B118">118</xref>).</p>
<p>CHI due to <italic>UCP2</italic> mutations can present with a variable clinical phenotype ranging from transient CHI to prolonged diazoxide-responsive HH (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B120">120</xref>, <xref ref-type="bibr" rid="B121">121</xref>). In one study <italic>UCP2</italic> variants were found in 2.4% of 211 diazoxide-responsive CHI patients (<xref ref-type="bibr" rid="B121">121</xref>). However, in a more recent study, no protein truncated variants have been detected in the <italic>UCP2</italic> gene among 206 diazoxide-responsive CHI patients (<xref ref-type="bibr" rid="B122">122</xref>). The only variant detected was considered to be a common polymorphism suggesting the necessity of further investigations of the <italic>UCP2</italic> role in CHI.</p>
</sec>
<sec>
<title>Somatic Overexpression of Hexokinase 1 (HK1) and CHI</title>
<p>Hexokinases are a group of enzymes that catalyse the initial step in the glucose utilization, phosphorylating the hexoses (including glucose) due to the enzyme ability to transfer a phosphate group from ATP to the substrates. The phosphorylated glucose (G6P) is the most important product which serves as an intermediate substrate for glycolysis, glycogen synthesis and pentose phosphate pathway. There are four hexokinase isoenzymes (HKI-IV) encoded by different genes, which are expressed at a different rate in various tissues (<xref ref-type="bibr" rid="B123">123</xref>). Of those, the HK-IV or GCK, has a much lower affinity for glucose and it is expressed only when an excessive amount of glucose is present. However, HK-I has about 50-fold higher affinity for glucose and at the low glucose levels, HK-I is the dominant isoenzyme catalyzing the glucose phosphorylation. The <italic>HK1</italic> gene, mapped on chromosome 10q22.1, encodes the enzyme HK-I. This enzyme predominatly serves G6P to the glycolytic pathway for energy production. Its enzymatic activity is allosterically inhibited by the end-product, G6P. The elevated G6P plays a signal transducing role indicating the lack of requirement of G6P for energy production, thus suppressing the expression of <italic>HK1</italic>. On the other hand, the <italic>HK1</italic> expression at low glucose levels is silenced in the pancreatic β-cells preventing from inappropriate insulin release (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>Recently, in a large family with dominant CHI, the responsible region has been mapped on chromosome 10, containing 48 genes (<xref ref-type="bibr" rid="B124">124</xref>). The first cases from this family had been reported by McQuarrie in 1954 as “idiopathic infantile hypoglycaemia” (<xref ref-type="bibr" rid="B120">120</xref>). Pinney et al. have investigated this large four-generation Northern European family with multiplex members with diazoxide-responsive hypoglycaemia and detected three novel variants in the <italic>HK1</italic> non-coding regions, suggesting the possibility of an inhibition of the <italic>HK1</italic> suppression in the β-cells as a result of a mutation (<xref ref-type="bibr" rid="B124">124</xref>). In an <italic>in-vitro</italic> study evaluating the pancreatic specimens of five CHI patients the role of the <italic>HK1</italic> overexpression has been shown in a group of β-cells (<xref ref-type="bibr" rid="B125">125</xref>). In these patients, although the K<sub>ATP</sub> channels were functional, there was an inappropriate insulin release in the presence of hypoglycaemia (<xref ref-type="bibr" rid="B125">125</xref>).</p>
</sec>
<sec>
<title>Mutations in Phosphoglucomutase 1 (PGM1) Gene and CHI</title>
<p>Phosphoglucomutases (PGM) are a group of enzymes that catalyse the interconversion of G6P and G1P (<xref ref-type="bibr" rid="B126">126</xref>). There are five different isoenzymes of PGM encoded by different genes. The enzyme phosphoglucomutase-1 is encoded by the <italic>PGM1</italic> gene, mapped on chromosome 1p31. It is a phosphotransferase that catalyses the reversible phosphate transfer between positions 1- and 6- of the glucose molecule, thus being involved in the glycogen synthesis, glycogen degradation and glycoprotein synthesis (<xref ref-type="bibr" rid="B126">126</xref>). Mutations in <italic>PGM1</italic> typically show a broad range of clinical manifestations resembling glycogenosis (Type XIV) as well as mixed-type congenital disorders of glycosylation (CDG type1t) (<xref ref-type="bibr" rid="B127">127</xref>–<xref ref-type="bibr" rid="B130">130</xref>). Recently, Tegtmeyer et al. have shown 19 patients from 16 families with a variety of clinical features suggesting CDG and atypical isoelectric focusing findings (<xref ref-type="bibr" rid="B128">128</xref>). Interestingly, the first clinical finding at birth (in 16 of 19 patients) was a bifid uvvula, but later the patients developed various manifestations including malignant hyperthermia, hepatopathy, secondary hypogonadism, short stature, hypoglycaemia, dilated cardiomyopathy and cardiac arrest. These patients were found to have recessive inactivating <italic>PGM1</italic> mutations, which has previously demonstrated to be related to the development of hypoglycaemia, similar to glycogenoses (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>). The <italic>PGM1</italic> mutations normally cause fasting hyperketotic hypoglycaemia, but in some cases a postprandial hypoketotic HH has been reported (<xref ref-type="bibr" rid="B131">131</xref>). It is proposed that the <italic>PGM1</italic> mutations cause HH due to the decreased threshold for glucose-mediated insulin release from the pancreatic cells (<xref ref-type="bibr" rid="B131">131</xref>). A later report (<xref ref-type="bibr" rid="B132">132</xref>) on two of the patients from the publication by Tegtmeyer (<xref ref-type="bibr" rid="B128">128</xref>) has shown more pronounced hypoglycosylation in childhood than in adults with a total PGM1-mRNA level reduced to 0.25% of that of normal controls. The study has also reported that hypoglycaemia might occur in <italic>PGM1</italic> deficient patients by starving and would be exaggerated by strong exercise (<xref ref-type="bibr" rid="B132">132</xref>).</p>
</sec>
<sec>
<title>Mutations in Phosphomannomutase 2 (PMM2) Gene and CHI</title>
<p>The enzyme phosphomannomutase 2 (PMM2) is involved in the N-glycosylation of proteins leading to glycopreotein synthesis. In the process of N-glycosylation large carbohydrate molecules (glycans) are covalently-attached to the N-terminal of the proteins (<xref ref-type="bibr" rid="B133">133</xref>). Although, the N-glycosylation does not change the conformation of protein structures, it reduces their dynamic fluctuation, leading to an enhanced protein stability (<xref ref-type="bibr" rid="B133">133</xref>). The PMM 2 enzyme is encoded by the <italic>PMM2</italic> gene, mapped on chromosome 16p13.2. The enzyme is a phosphotransferase catalyzing the interconversion of mannose-6-phosphate to mannose-1-phosphate which constitutes one of the early steps of the glycosylation process. Homozygous recessive mutations of <italic>PMM2</italic> are responsible for a variety of symptoms related to many organ systems, which include CDG type 1a (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>). The severity of the disease is closely associated with the remaining enzymatic activity, therefore, it is extremely variable ranging from a lethal embryopathy to a mild subclinical disease diagnosed in adulthood (<xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B137">137</xref>). HH has previously been reported as a part of the wide-range manifestations of CDG type Ia (<xref ref-type="bibr" rid="B138">138</xref>). Recently, in 17 children from 11 unrelated families, a recessively inherited mutation (c.-167G&gt;T) found in the <italic>PMM2</italic> gene promoter has been shown to result in a medically-responsive form of hyperinsulinism, associated with congenital polycystic kidney disease (<xref ref-type="bibr" rid="B139">139</xref>). This mutation changes the formation of the tissue-specific chromatin loop with an organ-specific gene expression which could explain the selective organ involvement in this condition. The functional analysis of the mutation has revealed dysregulated insulin secretion. Therefore, the <italic>PMM2</italic> gene might take a part in regulating insulin release from the pancreatic islets.</p>
</sec>
</sec>
<sec id="s4">
<title>CHI Due to Defects in Transcription Factors</title>
<sec>
<title>Muations in <italic>HNF1A&amp;4A</italic> and CHI</title>
<p>Transcription factors for nuclear hormone receptors (hepatocyte nuclear factors 1α and 4α (HNF1α and HNF4α<italic>)</italic> are expressed in the β-cells regulating the glucose-induced secretion of insulin (<xref ref-type="bibr" rid="B140">140</xref>–<xref ref-type="bibr" rid="B142">142</xref>). These factors are encoded by the <italic>HNF1A</italic> and <italic>HNF4A</italic> genes, respectively. Heterozygous inactivating variants of the genes cause two distinct conditions—CHI in newborns and maturity onset-diabetes (MODY type 1 and 3) in later life (<xref ref-type="bibr" rid="B143">143</xref>–<xref ref-type="bibr" rid="B146">146</xref>). This type of CHI due to <italic>HNF1A/HNF4A</italic> gene mutations is characterized with macrosomia and a clinical severity varying form mild transient hypoglycaemia to severe HH responsive to diazoxide therapy (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B143">143</xref>, <xref ref-type="bibr" rid="B147">147</xref>–<xref ref-type="bibr" rid="B149">149</xref>). In addition, a glycogenosis-like phenotype, characterized with glycogen accumulation in red blood cells, elevated liver enzymes and increased hepatic echogenicity on ultrasound examination, has been reported in CHI due to <italic>HNF4A</italic> gene mutations (<xref ref-type="bibr" rid="B150">150</xref>, <xref ref-type="bibr" rid="B151">151</xref>). Although CHI due to <italic>HNF1A</italic> and <italic>HNF4A</italic> mutations is rare, in some series of diazoxide-responsive HH, these mutations have been shown as one of the most common genetic etiology (<xref ref-type="bibr" rid="B149">149</xref>, <xref ref-type="bibr" rid="B152">152</xref>). The exact mechanisms by which the mutations in <italic>HNF4A</italic> and <italic>HNF1A</italic> could cause CHI are yet to be elucidated.</p>
</sec>
<sec>
<title>Mutations in FOXA2 and CHI</title>
<p>The forkhead box A2 transcription factor (FOXA2), also known as hepatocyte nuclear factor 3β (HNF3β), is encoded by <italic>FOXA2</italic> gene, localized on chromosome 20p11.21. It is required for the embryogenesis and organogenesis of endoderm-derived tissues including pancreas and forebrain structures including pitutary gland (<xref ref-type="bibr" rid="B153">153</xref>–<xref ref-type="bibr" rid="B157">157</xref>). FOXA2 is a major upstream regulator of Pdx1 which is a transcription factor implicated in the pancreas development (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B158">158</xref>). In mouse models it has been demonstrated that <italic>foxa2</italic> is necessary for the pancreatic α-cells differentiation and tissue-specific <italic>foxa2</italic> ablation leads to an imbalance in pancreatic β/α-cell ratio, profound hypoglucagonemia, inappropriate hyperinsulinaemia and hypoglycaemia (<xref ref-type="bibr" rid="B105">105</xref>, <xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B159">159</xref>). <italic>FOXA2</italic> also regulates the expression of <italic>KCNJ11</italic> and <italic>ABCC8</italic> genes and has a binding site on the intronic region of <italic>HADH</italic> gene playing a role in its transactivation (<xref ref-type="bibr" rid="B154">154</xref>, <xref ref-type="bibr" rid="B157">157</xref>, <xref ref-type="bibr" rid="B159">159</xref>).</p>
<p>The effects of <italic>FOXA2</italic> mutations on the pituitary function have previously been shown in cases with deletions of the proximal 20p11 region (<xref ref-type="bibr" rid="B160">160</xref>, <xref ref-type="bibr" rid="B161">161</xref>). The first mutation of <italic>FOXA2</italic> causing both pituitary dysfunction and CHI was recently reported in a case with congenital hypopituitarism, HH and endoderm-derived organ abnormalities (<xref ref-type="bibr" rid="B154">154</xref>). In this report a “<italic>de novo”</italic> heterozygous c.505T&gt;C (p.S169P) variant was detected in the <italic>FOXA2</italic> DNA-binding domain. The patient had a specific clinical presentation including hypoplasia of the anterior pituitary, absent neurohypophysis with interrupted pitutary stalk and hypoplasia of corpus collosum, associated with multiple pituitary hormone deficiency, persistent HH, craniofacial dysmorphism and abnormalities of organs of endodermal origin, e.g., liver, lungs and gastrointestinal tract (<xref ref-type="bibr" rid="B154">154</xref>). The authors have shown increased pancreatic <italic>hFOXA2</italic> expression in the immunohistochemical analysis of human embryos and lower transcriptional activity of hFOXA2-p.S169P variant in the functional analysis. Soon after the first report, another research group has reported a “<italic>de novo”</italic> heterozygous p.R257L mutation in an infant with congenital hypopituitarism, HH and atypical features including coarse face, increased distance between the orbits, low-set ears, and widely-spaced nipples (<xref ref-type="bibr" rid="B157">157</xref>). The functional analysis of this mutation demonstrated decreased <italic>SHH, Gli2</italic> and <italic>NKX2.2</italic> gene expression suggesting the importance of <italic>FOXA2</italic> mutation for the abnormal findings of the pituitary gland. Besides, the partially reduced expression of <italic>ABCC8, KCNJ11</italic>, and <italic>HADH</italic> has been suggested as an evidence for the mutation effects on the developement of HH in this case. Although, the molecular basis of the HH observed in the patients has not been fully elucidated, results from previously published mouse models and latest case reports suggest that mutation in <italic>FOXA2</italic> could potentially be a monogenic cause of CHI.</p>
</sec>
</sec>
<sec id="s5">
<title>Hyperinsulinaemic Hypoglycaemia due to Syndromes</title>
<p>HH has been described in several different syndromes (<xref ref-type="bibr" rid="B6">6</xref>) (<xref ref-type="table" rid="T2">Table 2</xref>). In most cases the underlying biochemical and molecular basis of the HH is unknown. Beckwith-Wiedemann syndrome (BWS), the most frequent syndromic condition associated with HH, is an overgrowth disorder characterized with macrosomia, macroglossia, neonatal hypoglycaemia, hemi-hypertrophy, omphalocele. BWS patients are also prone to the development of embryonal tumors (Wilm's tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma). BWS is linked to genetic and/or epigenetic abnormalities that alter the expression of imprinted genes on chromosome 11p15.5 (<xref ref-type="bibr" rid="B178">178</xref>). HH develops in approximately 50% of patients with BWS and in most cases it is transient. However, in some cases treatment with diazoxide will be required or a near total pancreatectomy (<xref ref-type="bibr" rid="B179">179</xref>). Although the molecular basis of HH due to BWS is not known, patients with BWS due to mosaic paternal isodisomy for chromosome 11 have the most severe hypoglycaemia (<xref ref-type="bibr" rid="B180">180</xref>). In one patient with BWS due to paternal uniparental disomy for this chromosome, electrophysiological studies of β-cells received at the time of surgery showed defects in pancreatic K<sub><bold>ATP</bold></sub> channels (<xref ref-type="bibr" rid="B162">162</xref>). HH also occurs in other genetic forms of BWS but tends to be milder and shows marked clinical heterogeneity even with the same genetic cause (<xref ref-type="bibr" rid="B181">181</xref>). In some BWS patients, HH may be the main clinical presentation (<xref ref-type="bibr" rid="B182">182</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Syndromic and metabolic causes of hyperinsulinaemic hypoglycaemia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Chromosome</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mode of inheritance</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>PRENATAL AND POSTNATAL OVERGROWTH SYNDROMES</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Beckwith-Wiedemann syndrome (<xref ref-type="bibr" rid="B162">162</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>IGF2/H19/</italic>
<break></break>
<italic>CDKN1C/</italic>
<break></break>
<italic>KCNQ1OT1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">11p15.5-15.4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant<break></break>Sporadic<break></break>Paternal uniparental disomy (patUPD)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sotos syndrome (<xref ref-type="bibr" rid="B163">163</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NSD1</italic>
<break></break>
<italic>NFIX</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">5q35.2-35.3<break></break>19p13.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant<break></break>Sporadic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Simpson-Golabi-Behmel syndrome (<xref ref-type="bibr" rid="B164">164</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GPC3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Xq26</td>
<td align="left" colspan="1" rowspan="1" valign="top">X-linked</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Perlman syndrome (<xref ref-type="bibr" rid="B165">165</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DIS3L2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">2q37</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CHROMOSOMAL ABNORMALITY SYNDROMES</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Turner syndrome (mosaic X loss) (<xref ref-type="bibr" rid="B166">166</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>KDM6A</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Xp11.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sporadic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Trisomy 13 (<xref ref-type="bibr" rid="B167">167</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CDX2, IPF1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Trisomy 13</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sporadic</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>POSTNATAL GROWTH FAILURE SYNDROMES</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kabuki syndrome (<xref ref-type="bibr" rid="B168">168</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>KMT2D</italic>
<break></break>
<italic>KDM6A</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">12q13.12<break></break>Xp11.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive<break></break>Sporadic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Costello syndrome (<xref ref-type="bibr" rid="B169">169</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>HRAS</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">11p15.5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant<break></break>Sporadic</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CONTIGUOUS GENE DELETION AFFECTING THE ABCC8 GENE</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Usher syndrome (<xref ref-type="bibr" rid="B170">170</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>USH1C</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">11p15.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>SYNDROMES LEADING TO ABNORMALITIES IN CALCIUM HOMOEOSTASIS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Timothy syndrome (<xref ref-type="bibr" rid="B171">171</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CACNA1C</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">3p21.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant<break></break>Sporadic</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>INSULIN RECEPTOR MUTATION</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin resistance syndrome (Donohue syndrome) (<xref ref-type="bibr" rid="B165">165</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>INSR</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">19p13.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CONGENITAL DISORDERS OF GLYCOSYLATION (CDG)</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDG Type Ia (<xref ref-type="bibr" rid="B138">138</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PMM2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">16p13.2-13.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDG Type Ib (<xref ref-type="bibr" rid="B172">172</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PMI</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">15q22-24</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDG Type Id (<xref ref-type="bibr" rid="B173">173</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>hALG3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">3q27</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>OTHER CAUSES</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Congenital central hypoventilation syndrome (<xref ref-type="bibr" rid="B174">174</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PHOX2B</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">4p12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant<break></break>Sporadic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tyrosinemia type 1(<xref ref-type="bibr" rid="B175">175</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>FAH</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">15q25.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal recessive</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Poland syndrome (<xref ref-type="bibr" rid="B176">176</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>UCMA</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">10p13-14</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sporadic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CHARGE syndrome (<xref ref-type="bibr" rid="B177">177</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CHD7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">8q12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autosomal dominant</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Kabuki syndrome is a rare genetic multisystem disorder characterized by developmental delay, “peculiar” face with elongated palpebral fissures, eversion of the lateral part of the lower eyelids, dermatoglyphic abnormalities with persistent fingertip pads, multiple congenital skeletal and visceral anomalies. Most of the cases with Kabuki syndrome have been associated with mutations in <italic>MLL2</italic> and <italic>KDM6A</italic> genes. HH has been reported in a few patients with Kabuki syndrome (<xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B183">183</xref>, <xref ref-type="bibr" rid="B184">184</xref>). However, a group has recently identified 10 patients with the syndrome (5 with MLL2 and 5 with KDM6A mutations) associated with HH. Following description of these 10 patients the authors have analyzed 100 HH patients with unknown etiology and detected Kabuki syndrome in one of those patients (1%) (<xref ref-type="bibr" rid="B185">185</xref>). They, therefore, have suggested that Kabuki syndrome might account for the etiology of HH in more patients. Nevertheless, the role/s of MLL2 and KDM6A in insulin release and glucose physiology is/are not ellucidated.</p>
<p>Sotos syndrome is also an overgrowth disorder. More than 75% of the cases with Sotos syndrome are due to intragenic mutations and deletions of the nuclear receptor binding SET-Domain 1 (NSD1) which is located at chromosome 5q35. Transient HH has been identified in several patients with Sotos syndrome (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B186">186</xref>). NSD1 is not known to be directly involved in regulating insulin secretion but patients with Sotos syndrome have alterations in the IGF-1 axis which could play a role in β-cell hyperplasia (<xref ref-type="bibr" rid="B187">187</xref>).</p>
<p>Turner syndrome (partial or total monosomy X) leads to short stature in females and is associated with impaired glucose tolerance later in life. Until recently, only three patients had been described with mild diazoxide-responsive HH (<xref ref-type="bibr" rid="B166">166</xref>, <xref ref-type="bibr" rid="B188">188</xref>, <xref ref-type="bibr" rid="B189">189</xref>), all being mosaic and having the ring X chromosome. Therefore, the abnormal mosaic expression of unknown X-chromosomal gene(s) in the β-cells was suggested leading to HH. However, recently, Gibson et al. reported that patients with Turner syndrome account for 10 out of 1,050 patients with HH suggesting a frequency of 48 times more than expected (<xref ref-type="bibr" rid="B190">190</xref>). The authors showed that a half of the girls with Turner syndrome and HH were medically unresponsive, with 3 patients requiring a partial or near-total pancreatectomy. Furthermore, all patients with HH had at least one monosomic cell line for the X–chromosome. In the same study the authors also demonstrated increased cytosolic calcium and enhanced amino acid-induced secretion of insulin in isolated pancreatic islets from 1 case and mouse islets exposed to a KDM6A inhibitor. They suggested that the KDM6A haploinsufficiency caused by mosaic X chromosome monosomy may explain the HH in Turner syndrome.</p>
<p>Timothy syndrome is a rare multi-system disorder characterized by lethal arrhythmias, congenital heart defects, syndactyly, immune deficiency, intermittent HH, intellectual disability, autism and autistic spectrum disorders. It is due to novel Ca(V)1.2 missense mutations (<xref ref-type="bibr" rid="B171">171</xref>). This is a calcium channel protein and theoretically could be connected with the regulation of the calcium homeostasis and secretion of insulin. One patient with another calcium channel gene (<italic>CACNA1D</italic>) mutation has been described with HH, hypotonia and congenital heart defects (<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>Other syndromes associated with HH include Costello (<xref ref-type="bibr" rid="B169">169</xref>), Trisomy 13 (<xref ref-type="bibr" rid="B167">167</xref>), central hypoventilation syndrome (<xref ref-type="bibr" rid="B174">174</xref>) and recently in CHARGE syndrome (<xref ref-type="bibr" rid="B177">177</xref>) (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusion</title>
<p>CHI is a complex condition characterized by upregulated β-cell insulin secretion leading to HH. Mutations in the <italic>ABCC8/KCNJ11</italic> genes of the K<sub>ATP</sub> channel result in the most severe forms of CHI. Abnormal variants in several other genes with a particular importance in the regulation of insulin release and several syndromic conditions may cause milder forms of HH. The molecular cause of CHI is determined in only half of the patients. The understanding of novel molecular mechanisms of the dysregulated release of insulin will provide novel insights into the pancreatic β-cells function.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>SG: literature review, wrote the section on non KATP causes of hyperinsulinism; SA-K: literature review, created all the figures and tables; HD: literature review, wrote the section on introduction and Katp channel causes of hyperinsulinism; KH: conception, planning, writing, organizing, checking and communicating.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The publication of this article was funded by the Qatar National Library.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Kelly</surname><given-names>A</given-names></name></person-group>. <article-title>Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children</article-title>. <source/>J Pediatr. (<year>2016</year>) <volume>168</volume>:<fpage>212</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2015.09.045</pub-id><pub-id pub-id-type="pmid">26490124</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aynsley-Green</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Saudubray</surname><given-names>JM</given-names></name><name><surname>Nihoul-Fékété</surname><given-names>C</given-names></name><name><surname>De Lonlay-Debeney</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Practical management of hyperinsulinism in infancy</article-title>. <source/>Arch Dis Child Fetal Neonatal Ed. (<year>2000</year>) <volume>82</volume>:<fpage>F98</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1136/fn.82.2.F98</pub-id><pub-id pub-id-type="pmid">10685981</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demirbilek</surname><given-names>H</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Congenital hyperinsulinism: diagnosis and treatment update</article-title>. <source/>J Clin Res Pediatr Endocrinol. (<year>2017</year>) <volume>9</volume>(<issue>Suppl. 2</issue>):<fpage>69</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.4274/jcrpe.2017.S007</pub-id><pub-id pub-id-type="pmid">29280746</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saint-Martin</surname><given-names>C</given-names></name><name><surname>Arnoux</surname><given-names>JB</given-names></name><name><surname>de Lonlay</surname><given-names>P</given-names></name><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name></person-group>. <article-title>KATP channel mutations in congenital hyperinsulinism</article-title>. <source/>Semin Pediatr Surg. (<year>2011</year>) <volume>20</volume>:<fpage>18</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1053/j.sempedsurg.2010.10.012</pub-id><pub-id pub-id-type="pmid">21185999</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group>. <article-title>Nutrient sensing in pancreatic islets: lessons from congenital hyperinsulinism and monogenic diabetes</article-title>. <source/>Ann N Y Acad Sci. (<year>2018</year>) <volume>1411</volume>:<fpage>65</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.13448</pub-id><pub-id pub-id-type="pmid">29044608</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Hyperinsulinism in developmental syndromes</article-title>. <source/>Endocr Dev. (<year>2009</year>) <volume>14</volume>:<fpage>95</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1159/000207480</pub-id><pub-id pub-id-type="pmid">19293578</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>S</given-names></name><name><surname>Tschen</surname><given-names>SI</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Hebrok</surname><given-names>M</given-names></name><name><surname>Matveyenko</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>DNA methylation directs functional maturation of pancreatic β-cells</article-title>. <source/>J Clin Invest. (<year>2015</year>) <volume>125</volume>:<fpage>2851</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1172/JCI79956</pub-id><pub-id pub-id-type="pmid">26098213</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintens</surname><given-names>R</given-names></name><name><surname>Hendrickx</surname><given-names>N</given-names></name><name><surname>Lemaire</surname><given-names>K</given-names></name><name><surname>Schuit</surname><given-names>F</given-names></name></person-group>. <article-title>Why expression of some genes is disallowed in beta cells</article-title>. <source/>Biochem Soc Trans. (<year>2008</year>) <volume>36</volume>:<fpage>300</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1042/BST0360300</pub-id><pub-id pub-id-type="pmid">18481946</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matschinsky</surname><given-names>FM</given-names></name></person-group>. <article-title>Banting lecture. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm</article-title>. <source/>Diabetes (<year>1996</year>) <volume>45</volume>:<fpage>223</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2337/diab.45.2.223</pub-id><pub-id pub-id-type="pmid">8549869</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name><name><surname>Madiraju</surname><given-names>SR</given-names></name></person-group>. <article-title>Metabolic signaling in fuel-induced insulin secretion</article-title>. <source/>Cell Metab. (<year>2013</year>) <volume>18</volume>:<fpage>162</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2013.05.018</pub-id><pub-id pub-id-type="pmid">23791483</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Rahman</surname><given-names>SA</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Hyperinsulinemic hypoglycemia - the molecular mechanisms</article-title>. <source/>Front Endocrinol. (<year>2016</year>) <volume>7</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2016.00029</pub-id><pub-id pub-id-type="pmid">27065949</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>DL</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name></person-group>. <article-title>Intracellular ATP directly blocks K+channels in pancreatic B-cells</article-title>. <source/>Nature (<year>1984</year>) <volume>311</volume>:<fpage>271</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">6090930</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashcroft</surname><given-names>FM</given-names></name><name><surname>Harrison</surname><given-names>DE</given-names></name><name><surname>Ashcroft</surname><given-names>SJ</given-names></name></person-group>. <article-title>Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells</article-title>. <source/>Nature (<year>1984</year>) <volume>312</volume>:<fpage>446</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">6095103</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doupnik</surname><given-names>CA</given-names></name><name><surname>Davidson</surname><given-names>N</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name></person-group>. <article-title>The inward rectifier potassium channel family</article-title>. <source/>Curr Opin Neurobiol. (<year>1995</year>) <volume>5</volume>:<fpage>268</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/0959-4388(95)80038-7</pub-id><pub-id pub-id-type="pmid">7580148</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>SA</given-names></name><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Molecular mechanisms of congenital hyperinsulinism</article-title>. <source/>J Mol Endocrinol. (<year>2015</year>) <volume>54</volume>:<fpage>R119</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1530/JME-15-0016</pub-id><pub-id pub-id-type="pmid">25733449</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Bryan</surname><given-names>L</given-names></name><name><surname>Nichols</surname><given-names>CG</given-names></name><name><surname>Wechsler</surname><given-names>SW</given-names></name><name><surname>Clement</surname><given-names>JP</given-names><suffix>IV</suffix></name><name><surname>Boyd</surname><given-names>AE</given-names><suffix>III</suffix></name><name><surname>González</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion</article-title>. <source/>Science (<year>1995</year>) <volume>268</volume>:<fpage>423</fpage>-<lpage>26</lpage>.<pub-id pub-id-type="pmid">7716547</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>N</given-names></name><name><surname>Gonoi</surname><given-names>T</given-names></name><name><surname>Clement</surname><given-names>JP</given-names></name><name><surname>Namba</surname><given-names>N</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Reconstitution of IKATP: An inward rectifier subunit plus the sulfonylurea receptor</article-title>. <source/>Science (<year>1995</year>) <volume>270</volume>:<fpage>1166</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1126/science.270.5239.1166</pub-id><pub-id pub-id-type="pmid">7502040</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerangue</surname><given-names>N</given-names></name><name><surname>Schwappach</surname><given-names>B</given-names></name><name><surname>Jan</surname><given-names>YN</given-names></name><name><surname>Jan</surname><given-names>LY</given-names></name></person-group>. <article-title>A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K (ATP) channels</article-title>. <source/>Neuron (<year>1999</year>) <volume>22</volume>:<fpage>537</fpage>-<lpage>48</lpage>.<pub-id pub-id-type="pmid">10197533</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Drain</surname><given-names>P</given-names></name></person-group>. <article-title>Open state destabilization by atp occupancy is mechanism speeding burst exit underlying KATP channel inhibition by ATP</article-title>. <source/>J Gen Physiol. (<year>2002</year>) <volume>119</volume>:<fpage>105</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.119.1.105</pub-id><pub-id pub-id-type="pmid">11773242</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Bryan</surname><given-names>L</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name></person-group>. <article-title>Molecular biology of adenosine triphosphate-sensitive potassium channels</article-title>. <source/>Endocr Rev. (<year>1999</year>) <volume>20</volume>:<fpage>101</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1210/er.20.2.101</pub-id><pub-id pub-id-type="pmid">10204114</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimono</surname><given-names>D</given-names></name><name><surname>Fujimoto</surname><given-names>S</given-names></name><name><surname>Mukai</surname><given-names>E</given-names></name><name><surname>Takehiro</surname><given-names>M</given-names></name><name><surname>Nabe</surname><given-names>K</given-names></name><name><surname>Radu</surname><given-names>RG</given-names></name><etal></etal></person-group>. <article-title>ATP enhances exocytosis of insulin secretory granules in pancreatic islets under Ca2+ depleted condition</article-title>. <source/>Diabetes Res Clin Pract. (<year>2005</year>) <volume>69</volume>:<fpage>216</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2005.01.010</pub-id><pub-id pub-id-type="pmid">16098917</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryer</surname><given-names>PE</given-names></name></person-group>. <article-title>Glucose counterregulation: prevention and correction of hypoglycemia in humans</article-title>. <source/>Am J Phys. (<year>1993</year>) <volume>264</volume>:<fpage>E149</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">8447379</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>CA</given-names></name></person-group>. <article-title>Perspective on the genetics and diagnosis of congenital hyperinsulinism disorders</article-title>. <source/>J Clin Endocrinol Metab. (<year>2016</year>) <volume>101</volume>:<fpage>815</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2015-3651</pub-id><pub-id pub-id-type="pmid">26908106</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Clauin</surname><given-names>S</given-names></name><name><surname>Bellanne-Chantelot</surname><given-names>C</given-names></name><name><surname>de Lonlay</surname><given-names>P</given-names></name><name><surname>Harries</surname><given-names>LW</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name><etal></etal></person-group>. <article-title>Update of mutations in the genes encoding the pancreatic beta-cell K (ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism</article-title>. <source/>Hum Mutat. (<year>2009</year>) <volume>30</volume>:<fpage>170</fpage>-<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20838</pub-id><pub-id pub-id-type="pmid">18767144</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>KE</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Boyajian</surname><given-names>L</given-names></name><name><surname>Shyng</surname><given-names>SL</given-names></name><name><surname>MacMullen</surname><given-names>C</given-names></name><name><surname>Hughes</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Genotype and phenotype correlations in 417 children with congenital hyperinsulinism</article-title>. <source/>J Clin Endocrinol Metab. (<year>2013</year>) <volume>98</volume>:<fpage>E355</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2012-2169</pub-id><pub-id pub-id-type="pmid">23275527</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohnike</surname><given-names>K</given-names></name><name><surname>Wieland</surname><given-names>I</given-names></name><name><surname>Barthlen</surname><given-names>W</given-names></name><name><surname>Vogelgesang</surname><given-names>S</given-names></name><name><surname>Empting</surname><given-names>S</given-names></name><name><surname>Mohnike</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Clinical and genetic evaluation of patients with KATP channel mutations from the German registry for congenital hyperinsulinism</article-title>. <source/>Horm Res Paediatr. (<year>2014</year>) <volume>81</volume>:<fpage>156</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1159/000356905</pub-id><pub-id pub-id-type="pmid">24401662</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Arya</surname><given-names>VB</given-names></name><name><surname>Shield</surname><given-names>JP</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism</article-title>. <source/>Eur J Endocrinol. (<year>2013</year>) <volume>168</volume>:<fpage>557</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-12-0673</pub-id><pub-id pub-id-type="pmid">23345197</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name><name><surname>Saint-Martin</surname><given-names>C</given-names></name><name><surname>Ribeiro</surname><given-names>MJ</given-names></name><name><surname>Vaury</surname><given-names>C</given-names></name><name><surname>Verkarre</surname><given-names>V</given-names></name><name><surname>Arnoux</surname><given-names>JB</given-names></name><etal></etal></person-group>. <article-title>ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism</article-title>. <source/>J Med Genet. (<year>2010</year>) <volume>47</volume>:<fpage>752</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2009.075416</pub-id><pub-id pub-id-type="pmid">20685672</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>SW</given-names></name></person-group>. <article-title>Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism</article-title>. <source/>Eur J Endocrinol. (<year>2011</year>) <volume>164</volume>:<fpage>919</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-11-0160</pub-id><pub-id pub-id-type="pmid">21422196</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>C</given-names></name><name><surname>Shepherd</surname><given-names>RM</given-names></name><name><surname>Squires</surname><given-names>PE</given-names></name><name><surname>Johnson</surname><given-names>PR</given-names></name><name><surname>James</surname><given-names>RF</given-names></name><name><surname>Milla</surname><given-names>PJ</given-names></name><etal></etal></person-group>. <article-title>Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy</article-title>. Nat Med (<year>1996</year>) <volume>2</volume>:<fpage>1344</fpage>-<lpage>47</lpage>.<pub-id pub-id-type="pmid">8946833</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Genetics of congenital hyperinsulinemic hypoglycemia</article-title>. <source/>Semin Pediatr Surg. (<year>2011</year>) <volume>20</volume>:<fpage>13</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1053/j.sempedsurg.2010.10.004</pub-id><pub-id pub-id-type="pmid">21185998</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekel</surname><given-names>B</given-names></name><name><surname>Lubin</surname><given-names>D</given-names></name><name><surname>Modan-Moses</surname><given-names>D</given-names></name><name><surname>Quint</surname><given-names>J</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Meyerovitch</surname><given-names>J</given-names></name></person-group>. <article-title>Compound heterozygosity for the common sulfonylurea receptor mutations can cause mild diazoxide-sensitive hyperinsulinism</article-title>. <source/>Clin Pediatr. (<year>2002</year>) <volume>41</volume>:<fpage>183</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1177/000992280204100310</pub-id><pub-id pub-id-type="pmid">11999683</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>A</given-names></name><name><surname>Aguilar-Bryan</surname><given-names>L</given-names></name></person-group>. <article-title>Assembly, maturation, and turnover of K(ATP) channel subunits</article-title>. <source/>J Biol Chem. (<year>2004</year>) <volume>279</volume>:<fpage>9080</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M311079200</pub-id><pub-id pub-id-type="pmid">14699091</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>FF</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>MacMullen</surname><given-names>C</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Shyng</surname><given-names>SL</given-names></name></person-group>. <article-title>Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue</article-title>. <source/>Diabetes (<year>2007</year>) <volume>56</volume>:<fpage>2339</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.2337/db07-0150</pub-id><pub-id pub-id-type="pmid">17575084</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>MacMullen</surname><given-names>C</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Shyng</surname><given-names>SL</given-names></name></person-group>. <article-title>A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels</article-title>. <source/>J Biol Chem. (<year>2006</year>) <volume>281</volume>:<fpage>3006</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M511875200</pub-id><pub-id pub-id-type="pmid">16332676</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartier</surname><given-names>EA</given-names></name><name><surname>Conti</surname><given-names>LR</given-names></name><name><surname>Vandenberg</surname><given-names>CA</given-names></name><name><surname>Shyng</surname><given-names>SL</given-names></name></person-group>. <article-title>Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2001</year>) <volume>98</volume>:<fpage>2882</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.051499698</pub-id><pub-id pub-id-type="pmid">11226335</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taschenberger</surname><given-names>G</given-names></name><name><surname>Mougey</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Lester</surname><given-names>LB</given-names></name><name><surname>LaFranchi</surname><given-names>S</given-names></name><name><surname>Shyng</surname><given-names>SL</given-names></name></person-group>. <article-title>Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels</article-title>. <source/>J Biol Chem. (<year>2002</year>) <volume>277</volume>:<fpage>7139</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M200363200</pub-id><pub-id pub-id-type="pmid">11867634</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname><given-names>TK</given-names></name><name><surname>Mankouri</surname><given-names>J</given-names></name><name><surname>Karnik</surname><given-names>R</given-names></name><name><surname>Kannan</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Munsey</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Sar1-GTPase-dependent ER exit of KATP channels revealed by a mutation causing congenital hyperinsulinism</article-title>. <source/>Hum Mol Genet. (<year>2009</year>) <volume>18</volume>:<fpage>2400</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp179</pub-id><pub-id pub-id-type="pmid">19357197</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marthinet</surname><given-names>E</given-names></name><name><surname>Bloc</surname><given-names>A</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><name><surname>Tanizawa</surname><given-names>Y</given-names></name><name><surname>Wehrle-Haller</surname><given-names>B</given-names></name><name><surname>Bancila</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function</article-title>. <source/>J Clin Endocrinol Metab. (<year>2005</year>) <volume>90</volume>:<fpage>5401</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-0202</pub-id><pub-id pub-id-type="pmid">15998776</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyng</surname><given-names>SL</given-names></name><name><surname>Ferrigni</surname><given-names>T</given-names></name><name><surname>Shepard</surname><given-names>JB</given-names></name><name><surname>Nestorowicz</surname><given-names>A</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Permutt</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy</article-title>. <source/>Diabetes (<year>1998</year>) <volume>47</volume>:<fpage>1145</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.47.7.1145</pub-id><pub-id pub-id-type="pmid">9648840</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>M</given-names></name><name><surname>Trapp</surname><given-names>S</given-names></name><name><surname>Tanizawa</surname><given-names>Y</given-names></name><name><surname>Kioka</surname><given-names>N</given-names></name><name><surname>Amachi</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Functional analysis of a mutant sulfonylurea receptor, SUR1-R1420C, that is responsible for persistent hyperinsulinemic hypoglycemia of infancy</article-title>. <source/>J Biol Chem. (<year>2000</year>) <volume>275</volume>:<fpage>41184</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M006503200</pub-id><pub-id pub-id-type="pmid">10993895</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinney</surname><given-names>SE</given-names></name><name><surname>MacMullen</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Hanna</surname><given-names>C</given-names></name><name><surname>Thornton</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations</article-title>. <source/>J Clin Invest. (<year>2008</year>) <volume>118</volume>:<fpage>2877</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1172/JCI35414</pub-id><pub-id pub-id-type="pmid">18596924</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>James</surname><given-names>CT</given-names></name><name><surname>McKiernan</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>AM</given-names></name><name><surname>Harmer</surname><given-names>SC</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/ KCNJ11 mutations</article-title>. <source/>Diabetologia (<year>2011</year>) <volume>54</volume>:<fpage>2575</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-011-2207-4</pub-id><pub-id pub-id-type="pmid">21674179</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>PS</given-names></name><name><surname>MacMullen</surname><given-names>C</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Ruchelli</surname><given-names>E</given-names></name><name><surname>Steinkrauss</surname><given-names>L</given-names></name><name><surname>Crane</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor</article-title>. <source/>Diabetes (<year>2003</year>) <volume>52</volume>:<fpage>2403</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.52.9.2403</pub-id><pub-id pub-id-type="pmid">12941782</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huopio</surname><given-names>H</given-names></name><name><surname>Reimann</surname><given-names>F</given-names></name><name><surname>Ashfield</surname><given-names>R</given-names></name><name><surname>Komulainen</surname><given-names>J</given-names></name><name><surname>Lenko</surname><given-names>HL</given-names></name><name><surname>Rahier</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1</article-title>. <source/>J Clin Invest. (<year>2000</year>) <volume>106</volume>:<fpage>897</fpage>-<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1172/JCI9804</pub-id><pub-id pub-id-type="pmid">11018078</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Ryan</surname><given-names>F</given-names></name><name><surname>Donath</surname><given-names>M</given-names></name><name><surname>Landau</surname><given-names>H</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Baker</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene</article-title>. <source/>Diabetes (<year>1999</year>) <volume>48</volume>:<fpage>1652</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.48.8.1652</pub-id><pub-id pub-id-type="pmid">10426386</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Işik</surname><given-names>E</given-names></name><name><surname>Demirbilek</surname><given-names>H</given-names></name><name><surname>Houghton</surname><given-names>JAL</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Congenital hyperinsulinism and evolution to sulfonylurea-responsive diabetes later in life due to a novel homozygous p.L171F ABCC8 mutation</article-title>. <source/>J Clin Res Pediatr Endocrinol. (<year>2018</year>). <pub-id pub-id-type="doi">10.4274/jcrpe.0077</pub-id> [Epub ahead of print].<pub-id pub-id-type="pmid">29739729</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Aziz</surname><given-names>QH</given-names></name><name><surname>Thomas</surname><given-names>AM</given-names></name><name><surname>Harmer</surname><given-names>SC</given-names></name><name><surname>Tinker</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8</article-title>. <source/>Hum Mol Genet. (<year>2015</year>) <volume>24</volume>:<fpage>5142</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv233</pub-id><pub-id pub-id-type="pmid">26092864</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Banerjee</surname><given-names>I</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>VV</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Dominantly acting ABCC8 mutations in patients with medically unresponsive hyperinsulinaemic hypoglycaemia</article-title>. <source/>Clin Genet. (<year>2011</year>) <volume>79</volume>:<fpage>582</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0004.2010.01476.x</pub-id><pub-id pub-id-type="pmid">20573158</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMullen</surname><given-names>CM</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Snider</surname><given-names>KE</given-names></name><name><surname>Tewson</surname><given-names>PH</given-names></name><name><surname>Becker</surname><given-names>SA</given-names></name><name><surname>Aziz</surname><given-names>AR</given-names></name><etal></etal></person-group>. <article-title>Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the β-cell sulfonylurea receptor SUR1</article-title>. <source/>Diabetes (<year>2011</year>) <volume>60</volume>:<fpage>1797</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.2337/db10-1631</pub-id><pub-id pub-id-type="pmid">21536946</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyng</surname><given-names>SL</given-names></name><name><surname>Ferrigni</surname><given-names>T</given-names></name><name><surname>Nichols</surname><given-names>CG</given-names></name></person-group>. <article-title>Regulation of KATP channel activity by diazoxide and MgADP</article-title>. <source/>J Gen Physiol. (<year>1997</year>) <volume>110</volume>:<fpage>643</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.110.6.643</pub-id><pub-id pub-id-type="pmid">9382893</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenkova</surname><given-names>K</given-names></name><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Obermannova</surname><given-names>B</given-names></name><name><surname>Elblova</surname><given-names>L</given-names></name><name><surname>Dusatkova</surname><given-names>P</given-names></name><name><surname>Sumnik</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Could a combination of heterozygous ABCC8 and KCNJ11 mutations cause congenital hyperinsulinism?</article-title>
<source/>J Pediatr Endocrinol Metab. (<year>2017</year>) <volume>30</volume>:<fpage>1311</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2017-0163</pub-id><pub-id pub-id-type="pmid">29127764</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damaj</surname><given-names>L</given-names></name><name><surname>le Lorch</surname><given-names>M</given-names></name><name><surname>Verkarre</surname><given-names>V</given-names></name><name><surname>Werl</surname><given-names>C</given-names></name><name><surname>Hubert</surname><given-names>L</given-names></name><name><surname>Nihoul-Fékété</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism</article-title>. <source/>J Clin Endocrinol Metab. (<year>2008</year>) <volume>93</volume>:<fpage>4941</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2008-0673</pub-id><pub-id pub-id-type="pmid">18796520</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lonlay</surname><given-names>P</given-names></name><name><surname>Fournet</surname><given-names>JC</given-names></name><name><surname>Rahier</surname><given-names>J</given-names></name><name><surname>Gross-Morand</surname><given-names>MS</given-names></name><name><surname>Poggi-Travert</surname><given-names>F</given-names></name><name><surname>Foussier</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy</article-title>. <source/>J Clin Invest. (<year>1997</year>) <volume>100</volume>:<fpage>802</fpage>–<lpage>07</lpage>. <pub-id pub-id-type="doi">10.1172/JCI119594</pub-id><pub-id pub-id-type="pmid">9259578</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuman</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Steele</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>PN</given-names></name><name><surname>Clericuzio</surname><given-names>C</given-names></name><name><surname>Zackai</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies</article-title>. <source/>Am J Med Genet. Part A (<year>2006</year>) <volume>140</volume>:<fpage>1497</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.31323</pub-id><pub-id pub-id-type="pmid">16770802</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sempoux</surname><given-names>C</given-names></name><name><surname>Capito</surname><given-names>C</given-names></name><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name><name><surname>Verkarre</surname><given-names>V</given-names></name><name><surname>de Lonlay</surname><given-names>P</given-names></name><name><surname>Aigrain</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy</article-title>. <source/>J Clin Endocrinol Metab. (<year>2011</year>) <volume>96</volume>:<fpage>3785</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-3032</pub-id><pub-id pub-id-type="pmid">21956412</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>VB</given-names></name><name><surname>Guemes</surname><given-names>M</given-names></name><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Gilbert</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Clinical and histological heterogeneity of congenital hyperinsulinism due to paternally inherited heterozygous ABCC8/KCNJ11 mutations</article-title>. <source/>Eur J Endocrinol. (<year>2014</year>) <volume>171</volume>:<fpage>685</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-14-0353</pub-id><pub-id pub-id-type="pmid">25201519</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiorana</surname><given-names>A</given-names></name><name><surname>Barbetti</surname><given-names>F</given-names></name><name><surname>Boiani</surname><given-names>A</given-names></name><name><surname>Rufini</surname><given-names>V</given-names></name><name><surname>Pizzoferro</surname><given-names>M</given-names></name><name><surname>Francalanci</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening</article-title>. <source/>Clin Endocrinol. (<year>2014</year>) <volume>81</volume>:<fpage>679</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1111/cen.12400</pub-id><pub-id pub-id-type="pmid">24383515</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>I</given-names></name><name><surname>Avatapalle</surname><given-names>B</given-names></name><name><surname>Padidela</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Cosgrove</surname><given-names>KE</given-names></name><name><surname>Clayton</surname><given-names>PE</given-names></name><etal></etal></person-group>. <article-title>Integrating genetic and imaging investigations into the clinical management of congenital hyperinsulinism</article-title>. <source/>Clin Endocrinol. (<year>2013</year>) <volume>78</volume>:<fpage>803</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/cen.12153</pub-id><pub-id pub-id-type="pmid">23347463</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon-Estebanez</surname><given-names>M</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Rigby</surname><given-names>L</given-names></name><name><surname>Bowden</surname><given-names>L</given-names></name><name><surname>Mohamed</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time</article-title>. <source/>Orphanet J Rare Dis. (<year>2016</year>) <volume>11</volume>:<fpage>163</fpage>. <pub-id pub-id-type="doi">10.1186/s13023-016-0547-3</pub-id><pub-id pub-id-type="pmid">27908292</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>FY</given-names></name><name><surname>Rajadurai</surname><given-names>VS</given-names></name><name><surname>Lu</surname><given-names>YT</given-names></name><name><surname>Chang</surname><given-names>KT</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><etal></etal></person-group>. <article-title>Paternally inherited ABCC8 mutation causing diffuse congenital hyperinsulinism</article-title>. <source/>Endocrinol Diabetes Metab Case Rep. (<year>2013</year>) <volume>2013</volume>:<fpage>130041</fpage>. <pub-id pub-id-type="doi">10.1530/EDM-13-0041</pub-id><pub-id pub-id-type="pmid">24616771</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Caswell</surname><given-names>R</given-names></name><name><surname>Damhuis</surname><given-names>A</given-names></name><name><surname>Vianey-Saban</surname><given-names>C</given-names></name><name><surname>Akcay</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Next-generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation</article-title>. <source/>Am J Hum Genet. (<year>2013</year>) <volume>92</volume>:<fpage>131</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.11.017</pub-id><pub-id pub-id-type="pmid">23273570</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Smith</surname><given-names>VV</given-names></name><name><surname>Ashworth</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Pierro</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism</article-title>. <source/>Diabetes (<year>2008</year>) <volume>57</volume>:<fpage>259</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.2337/db07-0998</pub-id><pub-id pub-id-type="pmid">17942822</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splawski</surname><given-names>I</given-names></name><name><surname>Timothy</surname><given-names>KW</given-names></name><name><surname>Vincent</surname><given-names>GM</given-names></name><name><surname>Atkinson</surname><given-names>DL</given-names></name><name><surname>Keating</surname><given-names>MT</given-names></name></person-group>. <article-title>Molecular basis of the long-QT syndrome associated with deafness</article-title>. <source/>N Engl J Med. (<year>1997</year>) <volume>336</volume>:<fpage>1562</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199705293362204</pub-id><pub-id pub-id-type="pmid">9164812</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torekov</surname><given-names>SS</given-names></name><name><surname>Iepsen</surname><given-names>E</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><etal></etal></person-group>. <article-title>KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia</article-title>. <source/>Diabetes (<year>2014</year>) <volume>63</volume>:<fpage>1315</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2337/db13-1454</pub-id><pub-id pub-id-type="pmid">24357532</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwashima</surname><given-names>Y</given-names></name><name><surname>Pugh</surname><given-names>W</given-names></name><name><surname>Depaoli</surname><given-names>AM</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Seino</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>GI</given-names></name><etal></etal></person-group>. <article-title>Expression of calcium channel mRNAs in rat pancreatic islets and downregulation after glucose infusion</article-title>. <source/>Diabetes (<year>1993</year>) <volume>42</volume>:<fpage>948</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.2337/diab.42.7.948</pub-id><pub-id pub-id-type="pmid">7685720</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Rahman</surname><given-names>SA</given-names></name><name><surname>Demirbilek</surname><given-names>H</given-names></name><name><surname>Guemes</surname><given-names>M</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Hyperinsulinaemic hypoglycaemia in children and adults</article-title>. <source/>Lancet Diabetes Endocrinol. (<year>2017</year>) <volume>5</volume>:<fpage>729</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(16)30323-0</pub-id><pub-id pub-id-type="pmid">27915035</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>UI</given-names></name><name><surname>Goh</surname><given-names>G</given-names></name><name><surname>Stolting</surname><given-names>G</given-names></name><name><surname>de Oliveira</surname><given-names>RC</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Overton</surname><given-names>JD</given-names></name><etal></etal></person-group>. <article-title>Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism</article-title>. <source/>Nat Genet. (<year>2013</year>) <volume>45</volume>:<fpage>1050</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2695</pub-id><pub-id pub-id-type="pmid">23913001</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Vairo</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>MB</given-names></name><name><surname>Caswell</surname><given-names>R</given-names></name><name><surname>Laver</surname><given-names>TW</given-names></name><name><surname>Lango Allen</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia</article-title>. <source/>Pediatr Diabetes (<year>2017</year>) <volume>18</volume>:<fpage>320</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/pedi.12512</pub-id><pub-id pub-id-type="pmid">28318089</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuff</surname><given-names>MA</given-names></name><name><surname>Shirazi-Beechey</surname><given-names>SP</given-names></name></person-group>. <article-title>The human monocarboxylate transporter, MCT1: genomic organization and promoter analysis</article-title>. <source/>Biochem Biophys Res Commun. (<year>2002</year>) <volume>292</volume>:<fpage>1048</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.2002.6763</pub-id><pub-id pub-id-type="pmid">11944921</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullen</surname><given-names>TJ</given-names></name><name><surname>Sylow</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Halestrap</surname><given-names>AP</given-names></name><name><surname>Richter</surname><given-names>EA</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name></person-group>. <article-title>Overexpression of monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic beta-cells leads to relative hyperinsulinism during exercise</article-title>. <source/>Diabetes (<year>2012</year>) <volume>61</volume>:<fpage>1719</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2337/db11-1531</pub-id><pub-id pub-id-type="pmid">22522610</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otonkoski</surname><given-names>T</given-names></name><name><surname>Kaminen</surname><given-names>N</given-names></name><name><surname>Ustinov</surname><given-names>J</given-names></name><name><surname>Lapatto</surname><given-names>R</given-names></name><name><surname>Meissner</surname><given-names>T</given-names></name><name><surname>Mayatepek</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release</article-title>. <source/>Diabetes (<year>2003</year>) <volume>52</volume>:<fpage>199</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.52.1.199</pub-id><pub-id pub-id-type="pmid">12502513</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosur</surname><given-names>M</given-names></name><name><surname>Jeha</surname><given-names>GS</given-names></name></person-group>. <article-title>A novel intragenic SLC16A1 mutation associated with congenital hyperinsulinism</article-title>. <source/>Glob Pediatr Health (<year>2017</year>) <volume>4</volume>:<fpage>2333794X17703462</fpage>. <pub-id pub-id-type="doi">10.1177/2333794X17703462</pub-id><pub-id pub-id-type="pmid">28491926</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Dauwerse</surname><given-names>JG</given-names></name><name><surname>Moschonas</surname><given-names>NK</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>van Loon</surname><given-names>AP</given-names></name></person-group>
<article-title>Three human glutamate dehydrogenase genes (GLUD1, GLUDP2, and GLUDP3) are located on chromosome 10q, but are not closely physically linked</article-title>. <source/>Genomics (<year>1993</year>) <volume>17</volume>:<fpage>676</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1006/geno.1993.1389</pub-id><pub-id pub-id-type="pmid">8244384</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>RC</given-names></name><name><surname>Daniel</surname><given-names>RM</given-names></name></person-group>. <article-title>L-glutamate dehydrogenases: distribution, properties and mechanism</article-title>. <source/>Comp Biochem Physiol B (<year>1993</year>) <volume>106</volume>:<fpage>767</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/0305-0491(93)90031-Y</pub-id><pub-id pub-id-type="pmid">8299344</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Lieu</surname><given-names>YK</given-names></name><name><surname>Hsu</surname><given-names>BY</given-names></name><name><surname>Burlina</surname><given-names>AB</given-names></name><name><surname>Greenberg</surname><given-names>CR</given-names></name><name><surname>Hopwood</surname><given-names>NJ</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene</article-title>. <source/>N Engl J Med. (<year>1998</year>) <volume>338</volume>:<fpage>1352</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199805073381904</pub-id><pub-id pub-id-type="pmid">9571255</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Najafi</surname><given-names>H</given-names></name><name><surname>Daikhin</surname><given-names>Y</given-names></name><name><surname>Nissim</surname><given-names>IB</given-names></name><name><surname>Collins</surname><given-names>HW</given-names></name><name><surname>Yudkoff</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Regulation of leucine-stimulated insulin secretion and glutamine metabolism in isolated rat islets</article-title>. <source/>J Biol Chem. (<year>2003</year>) <volume>278</volume>:<fpage>2853</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M210577200</pub-id><pub-id pub-id-type="pmid">12444083</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>A</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name></person-group>. <article-title>The structure and allosteric regulation of glutamate dehydrogenase</article-title>. <source/>Neurochem Int. (<year>2011</year>) <volume>59</volume>:<fpage>445</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2010.10.017</pub-id><pub-id pub-id-type="pmid">21070828</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kibbey</surname><given-names>RG</given-names></name><name><surname>Choi</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Cabrera</surname><given-names>O</given-names></name><name><surname>Pongratz</surname><given-names>RL</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Mitochondrial GTP insensitivity contributes to hypoglycemia in hyperinsulinemia hyperammonemia by inhibiting glucagon release</article-title>. <source/>Diabetes (<year>2014</year>) <volume>63</volume>:<fpage>4218</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2337/db14-0783</pub-id><pub-id pub-id-type="pmid">25024374</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Kutyna</surname><given-names>K</given-names></name><name><surname>Hsu</surname><given-names>BY</given-names></name><name><surname>Ming</surname><given-names>JE</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators</article-title>. <source/>Diabetes (<year>2000</year>) <volume>49</volume>:<fpage>667</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.49.4.667</pub-id><pub-id pub-id-type="pmid">10871207</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santer</surname><given-names>R</given-names></name><name><surname>Kinner</surname><given-names>M</given-names></name><name><surname>Passarge</surname><given-names>M</given-names></name><name><surname>Superti-Furga</surname><given-names>A</given-names></name><name><surname>Mayatepek</surname><given-names>E</given-names></name><name><surname>Meissner</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Novel missense mutations outside the allosteric domain of glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism–hyperammonemia syndrome</article-title>. <source/>Hum Genet. (<year>2001</year>) <volume>108</volume>:<fpage>66</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/s004390000432</pub-id><pub-id pub-id-type="pmid">11214910</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Okano</surname><given-names>Y</given-names></name><name><surname>Inada</surname><given-names>H</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Hase</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Molecular characterisation of glutamate dehydrogenase gene defects in Japanese patients with congenital hyperinsulinism/hyperammonaemia</article-title>. <source/>Eur J Hum Genet. (<year>2001</year>) <volume>9</volume>:<fpage>931</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200749</pub-id><pub-id pub-id-type="pmid">11840195</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>CA</given-names></name></person-group>. <article-title>Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism</article-title>. <source/>Mol Genet Metab. (<year>2004</year>) <volume>81</volume>:<fpage>S45</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2003.10.013</pub-id><pub-id pub-id-type="pmid">15050973</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senniappan</surname><given-names>S</given-names></name><name><surname>Arya</surname><given-names>VB</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>The molecular mechanisms, diagnosis and management of congenital hyperinsulinism</article-title>. <source/>Ind J Endocrinol Metab. (<year>2013</year>) <volume>17</volume>:<fpage>19</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.4103/2230-8210.107822</pub-id><pub-id pub-id-type="pmid">23776849</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treberg</surname><given-names>JR</given-names></name><name><surname>Clow</surname><given-names>KA</given-names></name><name><surname>Greene</surname><given-names>KA</given-names></name><name><surname>Brosnan</surname><given-names>ME</given-names></name><name><surname>Brosnan</surname><given-names>JT</given-names></name></person-group>. <article-title>Systemic activation of glutamate dehydrogenase increases renal ammoniagenesis: implications for the hyperinsulinism/hyperammonemia syndrome</article-title>. <source/>Am J Phys Endocrinol Metab. (<year>2010</year>) <volume>298</volume>:<fpage>E1219</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00028.2010</pub-id><pub-id pub-id-type="pmid">20332361</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Fulton</surname><given-names>P</given-names></name><name><surname>Chakrapani</surname><given-names>A</given-names></name><name><surname>Chadefaux</surname><given-names>B</given-names></name><name><surname>Ben-Omran</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinism-hyperammonaemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations</article-title>. <source/>Eur J Endocrinol. (<year>2009</year>) <volume>161</volume>:<fpage>731</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-09-0615</pub-id><pub-id pub-id-type="pmid">19690084</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>BY</given-names></name><name><surname>Kelly</surname><given-names>A</given-names></name><name><surname>Thornton</surname><given-names>PS</given-names></name><name><surname>Greenberg</surname><given-names>CR</given-names></name><name><surname>Dilling</surname><given-names>LA</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name></person-group>. <article-title>Proteinsensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome</article-title>. <source/>J Pediatr. (<year>2001</year>) <volume>138</volume>:<fpage>383</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1067/mpd.2001.111818</pub-id><pub-id pub-id-type="pmid">11241047</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahi-Buisson</surname><given-names>N</given-names></name><name><surname>Roze</surname><given-names>E</given-names></name><name><surname>Dionisi</surname><given-names>C</given-names></name><name><surname>Escande</surname><given-names>F</given-names></name><name><surname>Valayannopoulos</surname><given-names>V</given-names></name><name><surname>Feillet</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Neurological aspects of hyperinsulinism-hyperammonaemia syndrome</article-title>. <source/>Dev Med Child Neurol. (<year>2008</year>) <volume>50</volume>:<fpage>945</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2008.03114.x</pub-id><pub-id pub-id-type="pmid">19046187</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrosse-Antle</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Boodhansingh</surname><given-names>KE</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><etal></etal></person-group>. <article-title>A severe case of hyperinsulinism due to hemizygous activating mutation of glutamate dehydrogenase</article-title>. <source/>Pediatr Diabetes (<year>2017</year>) <volume>18</volume>:<fpage>911</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/pedi.12507</pub-id><pub-id pub-id-type="pmid">28165182</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iynedjian</surname><given-names>PB</given-names></name><name><surname>Mobius</surname><given-names>G</given-names></name><name><surname>Seitz</surname><given-names>HJ</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name><name><surname>Renold</surname><given-names>AE</given-names></name></person-group>. <article-title>Tissue-specific expression of glucokinase: identification of the gene product in liver and pancreatic islets</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1986</year>) <volume>83</volume>:<fpage>1998</fpage>–<lpage>2001</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.83.7.1998</pub-id><pub-id pub-id-type="pmid">3515342</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matschinsky</surname><given-names>FM</given-names></name></person-group>. <article-title>Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics</article-title>. <source/>Diabetes (<year>2002</year>) <volume>51</volume>:<fpage>S394</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S394</pub-id><pub-id pub-id-type="pmid">12475782</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelent</surname><given-names>D</given-names></name><name><surname>Najafi</surname><given-names>H</given-names></name><name><surname>Odili</surname><given-names>S</given-names></name><name><surname>Buettger</surname><given-names>C</given-names></name><name><surname>Weik-Collins</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Glucokinase and glucose homeostasis: proven concepts and new ideas</article-title>. <source/>Biochem Soc Trans. (<year>2005</year>) <volume>33</volume>:<fpage>306</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1042/BST0330306</pub-id><pub-id pub-id-type="pmid">15667334</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osbak</surname><given-names>KK</given-names></name><name><surname>Colclough</surname><given-names>K</given-names></name><name><surname>Saint-Martin</surname><given-names>C</given-names></name><name><surname>Beer</surname><given-names>NL</given-names></name><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia</article-title>. <source/>Hum Mutat. (<year>2009</year>) <volume>30</volume>:<fpage>1512</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21110</pub-id><pub-id pub-id-type="pmid">19790256</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbetti</surname><given-names>F</given-names></name><name><surname>Cobo-Vuilleumier</surname><given-names>N</given-names></name><name><surname>Dionisi-Vici</surname><given-names>C</given-names></name><name><surname>Toni</surname><given-names>S</given-names></name><name><surname>Ciampalini</surname><given-names>P</given-names></name><name><surname>Massa</surname><given-names>O</given-names></name><etal></etal></person-group>. <article-title>Opposite clinical phenotypes of glucokinase disease:description of a novel activating mutation and contiguous inactivating mutations in human Glucokinase (GCK)</article-title>. <source/>Gene Mol Endocrinol. (<year>2009</year>) <volume>23</volume>:<fpage>1983</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1210/me.2009-0094</pub-id><pub-id pub-id-type="pmid">19884385</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Conformational transition pathway in the activation process of allosteric glucokinase</article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e55857</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0055857</pub-id><pub-id pub-id-type="pmid">23409066</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralph</surname><given-names>EC</given-names></name><name><surname>Thomson</surname><given-names>J</given-names></name><name><surname>Almaden</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name></person-group>. <article-title>Glucose modulation of glucokinase activation by small molecules</article-title>. <source/>Biochemistry (<year>2008</year>) <volume>47</volume>:<fpage>5028</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1021/bi702516y</pub-id><pub-id pub-id-type="pmid">18370405</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christesen</surname><given-names>HB</given-names></name><name><surname>Tribble</surname><given-names>ND</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Sandal</surname><given-names>T</given-names></name><name><surname>Brusgaard</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Activating Glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation</article-title>. <source/>Eur J Endocrinol. (<year>2008</year>) <volume>159</volume>:<fpage>27</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-08-0203</pub-id><pub-id pub-id-type="pmid">18450771</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Gutierrez-Nogues</surname><given-names>A</given-names></name><name><surname>Fernandez-Ramos</surname><given-names>C</given-names></name><name><surname>Velayos</surname><given-names>T</given-names></name><name><surname>Vela</surname><given-names>A; Spanish Congenital Hyperinsulinism Group</given-names></name><etal></etal></person-group>. <article-title>Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization</article-title>. <source/>Clin Endocrinol. (<year>2017</year>) <volume>86</volume>:<fpage>778</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/cen.13318</pub-id><pub-id pub-id-type="pmid">28247534</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Kyo</surname><given-names>C</given-names></name><name><surname>Yonemoto</surname><given-names>T</given-names></name><name><surname>Kosugi</surname><given-names>R</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group>. <article-title>Asymptomatic congenital hyperinsulinism due to a Glucokinase-activating mutation, treated as adrenal insufficiency for twelve years</article-title>. <source/>Case Rep Endocrinol. (<year>2017</year>) <volume>2017</volume>:<fpage>4709262</fpage>. <pub-id pub-id-type="doi">10.1155/2017/4709262</pub-id><pub-id pub-id-type="pmid">28163940</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayed</surname><given-names>S</given-names></name><name><surname>Langdon</surname><given-names>DR</given-names></name><name><surname>Odili</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Buettger</surname><given-names>C</given-names></name><name><surname>Schiffman</surname><given-names>AB</given-names></name><etal></etal></person-group>. <article-title>Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations</article-title>. <source/>Diabetes (<year>2009</year>) <volume>58</volume>:<fpage>1419</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2337/db08-1792</pub-id><pub-id pub-id-type="pmid">19336674</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajala</surname><given-names>ON</given-names></name><name><surname>Huffman</surname><given-names>DM</given-names></name><name><surname>Ghobrial</surname><given-names>II</given-names></name></person-group>. <article-title>Glucokinase mutation-a rare cause of recurrent hypoglycemia in adults: a case report and literature review</article-title>. <source/>J Community Hosp Intern Med Perspect. (<year>2016</year>) <volume>6</volume>:<fpage>32983</fpage>. <pub-id pub-id-type="doi">10.3402/jchimp.v6.32983</pub-id><pub-id pub-id-type="pmid">27802864</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassem</surname><given-names>S</given-names></name><name><surname>Bhandari</surname><given-names>S</given-names></name><name><surname>Rodriguez-Bada</surname><given-names>P</given-names></name><name><surname>Motaghedi</surname><given-names>R</given-names></name><name><surname>Heyman</surname><given-names>M</given-names></name><name><surname>García-Gimeno</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Large islets, beta cell proliferation, and a glucokinase mutation</article-title>. <source/>N Engl J Med. (<year>2010</year>) <volume>362</volume>:<fpage>1348</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc0909845</pub-id><pub-id pub-id-type="pmid">20375417</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuesta-Munoz</surname><given-names>AL</given-names></name><name><surname>Huopio</surname><given-names>H</given-names></name><name><surname>Otonkoski</surname><given-names>T</given-names></name><name><surname>Gomez-Zumaquero</surname><given-names>JM</given-names></name><name><surname>Näntö-Salonen</surname><given-names>K</given-names></name><name><surname>Rahier</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation</article-title>. <source/>Diabetes (<year>2004</year>) <volume>53</volume>:<fpage>2164</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.53.8.2164</pub-id><pub-id pub-id-type="pmid">15277402</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vredendaal</surname><given-names>PJ</given-names></name><name><surname>van den Berg</surname><given-names>IE</given-names></name><name><surname>Malingre</surname><given-names>HE</given-names></name><name><surname>Stroobants</surname><given-names>AK</given-names></name><name><surname>Olde Weghuis</surname><given-names>DE</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name></person-group>. <article-title>Human short-chain L-3-hydroxyacyl-CoA dehydrogenase: cloning and characterization of the coding sequence</article-title>. <source/>Biochem Biophys Res Commun. (<year>1996</year>) <volume>223</volume>:<fpage>718</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1996.0961</pub-id><pub-id pub-id-type="pmid">8687463</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantz</surname><given-names>KA</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Brestelli</surname><given-names>JE</given-names></name><name><surname>Friedman</surname><given-names>JR</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group>. <article-title>Foxa2 regulates multiple pathways of insulin secretion</article-title>. <source/>J Clin Invest. (<year>2004</year>) <volume>114</volume>:<fpage>512</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1172/JCI21149</pub-id><pub-id pub-id-type="pmid">15314688</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity</article-title>. <source/>J Clin Endocrinol Metab. (<year>2009</year>) <volume>94</volume>:<fpage>2221</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2009-0423</pub-id><pub-id pub-id-type="pmid">19417036</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>PT</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Aynsley Green</surname><given-names>A</given-names></name><name><surname>Edginton</surname><given-names>M</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Krywawych</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinism in short chain L 3 hydroxyacyl CoA dehydrogenase deficiency reveals the importance of beta oxidation in insulin secretion</article-title>. <source/>J Clin Invest. (<year>2001</year>) <volume>108</volume>:<fpage>457</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1172/JCI200111294</pub-id><pub-id pub-id-type="pmid">11489939</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>E</given-names></name><name><surname>Cardoso</surname><given-names>ML</given-names></name><name><surname>Rodrigues</surname><given-names>E</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Short chain 3 hydroxyacyl CoA dehydrogenase deficiency: the clinical relevance of an early diagnosis and report of four new cases</article-title>. <source/>J Inherit Metab Dis. (<year>2011</year>) <volume>34</volume>:<fpage>835</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-011-9287-7</pub-id><pub-id pub-id-type="pmid">21347589</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Palladino</surname><given-names>A</given-names></name><name><surname>Narayan</surname><given-names>S</given-names></name><name><surname>Russell</surname><given-names>LK</given-names></name><name><surname>Sayed</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Mechanism of hyperinsulinism in short chain 3 hydroxyacyl CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase</article-title>. <source/>J Biol Chem. (<year>2010</year>) <volume>285</volume>:<fpage>31806</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.123638</pub-id><pub-id pub-id-type="pmid">20670938</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslegrave</surname><given-names>AJ</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Novel insights into fatty acid oxidation, amino acid metabolism, and insulin secretion from studying patients with loss of function mutations in 3-hydroxyacyl-CoA dehydrogenase</article-title>. <source/>J Clin Endocrinol Metab. (<year>2013</year>) <volume>98</volume>:<fpage>496</fpage>–<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2012-3134</pub-id><pub-id pub-id-type="pmid">23253615</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babiker</surname><given-names>O</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Al Girim</surname><given-names>H</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Senniappan</surname><given-names>S</given-names></name></person-group>. <article-title>Protein-induced hyperinsulinaemic hypoglycaemia due to a homozygous HADH mutation in three siblings of a Saudi family</article-title>. <source/>J Pediatr Endocrinol Metab. (<year>2015</year>) <volume>28</volume>:<fpage>1073</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2015-0033</pub-id><pub-id pub-id-type="pmid">25915078</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Locke</surname><given-names>JM</given-names></name><name><surname>Akcay</surname><given-names>T</given-names></name><name><surname>Simsek</surname><given-names>E</given-names></name><name><surname>Alaei</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Genome wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide responsive hyperinsulinemic hypoglycemia in consanguineous pedigrees</article-title>. <source/>J Clin Endocrinol Metab. (<year>2011</year>) <volume>96</volume>:<fpage>E498</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-1906</pub-id><pub-id pub-id-type="pmid">21252247</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleury</surname><given-names>C</given-names></name><name><surname>Neverova</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Raimbault</surname><given-names>S</given-names></name><name><surname>Champigny</surname><given-names>O</given-names></name><name><surname>Levi-Meyrueis</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia</article-title>. <source/>Nat Genet. (<year>1997</year>) <volume>15</volume>:<fpage>269</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/ng0397-269</pub-id><pub-id pub-id-type="pmid">9054939</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Barroso</surname><given-names>MM</given-names></name><name><surname>Giurgea</surname><given-names>I</given-names></name><name><surname>Bouillaud</surname><given-names>F</given-names></name><name><surname>Anedda</surname><given-names>A</given-names></name><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name><name><surname>Hubert</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion</article-title>. <source/>PLoS ONE (<year>2008</year>) <volume>3</volume>:<fpage>e3850</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0003850</pub-id><pub-id pub-id-type="pmid">19065272</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>CY</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name></person-group>. <article-title>A significant portion of mitochondrial proton leak in intact thymocytes depends on expression of UCP2</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2002</year>) <volume>99</volume>:<fpage>118</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.012410699</pub-id><pub-id pub-id-type="pmid">11756659</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>DG</given-names></name></person-group>. <article-title>The pancreatic beta-cell: a bioenergetic perspective</article-title>. <source/>Physiol Rev. (<year>2016</year>) <volume>96</volume>:<fpage>1385</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00009.2016</pub-id><pub-id pub-id-type="pmid">27582250</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CB</given-names></name><name><surname>Harper</surname><given-names>ME</given-names></name></person-group>. <article-title>Uncoupling proteins: role in insulin resistance and insulin insufficiency</article-title>. <source/>Curr Diabetes Rev. (<year>2006</year>) <volume>2</volume>:<fpage>271</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.2174/157339906777950660</pub-id><pub-id pub-id-type="pmid">18220632</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CB</given-names></name><name><surname>De Leo</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>JW</given-names></name><name><surname>McQuaid</surname><given-names>TS</given-names></name><name><surname>Ha</surname><given-names>XF</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action</article-title>. <source/>Diabetes (<year>2001</year>) <volume>50</volume>:<fpage>1302</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.50.6.1302</pub-id><pub-id pub-id-type="pmid">11375330</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Affourtit</surname><given-names>C</given-names></name><name><surname>Brand</surname><given-names>MD</given-names></name></person-group>. <article-title>Uncoupling protein-2 contributes significantly to high mitochondrial proton leak in INS-1E insulinoma cells and attenuates glucose-stimulated insulin secretion</article-title>. <source/>Biochem J. (<year>2008</year>) <volume>409</volume>:<fpage>199</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20070954</pub-id><pub-id pub-id-type="pmid">17824844</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuarrie</surname><given-names>I</given-names></name></person-group>. <article-title>Idiopathic spontaneously occurring hypoglycemia in infants; clinical significance of problem and treatment</article-title>. <source/>AMA Am J Dis Child (<year>1954</year>) <volume>87</volume>:<fpage>399</fpage>–<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1954.02050090387001</pub-id><pub-id pub-id-type="pmid">13147532</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>CT</given-names></name><name><surname>Boodhansingh</surname><given-names>KE</given-names></name><name><surname>Paradies</surname><given-names>E</given-names></name><name><surname>Giuseppe</surname><given-names>F</given-names></name><name><surname>Steinkrauss</surname><given-names>LJ</given-names></name><name><surname>Topor</surname><given-names>LS</given-names></name><etal></etal></person-group>
<article-title>Novel hypoglycemia phenotype in congenital hyperinsulinism due to dominant mutations of Uncoupling Protein 2 (UCP2)</article-title>. <source/>J Clin Endocrinol Metab. (<year>2017</year>) <volume>102</volume>:<fpage>942</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2016-3164</pub-id><pub-id pub-id-type="pmid">27967291</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laver</surname><given-names>TW</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Caswell</surname><given-names>R</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name></person-group>
<article-title>Analysis of large-scale sequencing cohorts does not support the role of variants in UCP2 as a cause of hyperinsulinaemic hypoglycaemia</article-title>. <source/>Hum Mutat. (<year>2017</year>) <volume>38</volume>:<fpage>1442</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/humu.23289</pub-id><pub-id pub-id-type="pmid">28681398</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>JE</given-names></name></person-group>. <article-title>Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function</article-title>. <source/>J Exp Biol. (<year>2003</year>) <volume>206</volume>:<fpage>2049</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1242/jeb.00241</pub-id><pub-id pub-id-type="pmid">12756287</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinney</surname><given-names>SE</given-names></name><name><surname>Ganapathy</surname><given-names>K</given-names></name><name><surname>Bradfield</surname><given-names>J</given-names></name><name><surname>Stokes</surname><given-names>D</given-names></name><name><surname>Sasson</surname><given-names>A</given-names></name><name><surname>Mackiewicz</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Dominant form of congenital hyperinsulinism maps to HK1 region on 10q</article-title>. <source/>Horm Res Paediatr. (<year>2013</year>) <volume>80</volume>:<fpage>18</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1159/000351943</pub-id><pub-id pub-id-type="pmid">23859901</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henquin</surname><given-names>JC</given-names></name><name><surname>Sempoux</surname><given-names>C</given-names></name><name><surname>Marchandise</surname><given-names>J</given-names></name><name><surname>Godecharles</surname><given-names>S</given-names></name><name><surname>Guiot</surname><given-names>Y</given-names></name><name><surname>Nenquin</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of beta-cells</article-title>. <source/>Diabetes (<year>2013</year>) <volume>62</volume>:<fpage>1689</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.2337/db12-1414</pub-id><pub-id pub-id-type="pmid">23274908</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putt</surname><given-names>W</given-names></name><name><surname>Ives</surname><given-names>JH</given-names></name><name><surname>Hollyoake</surname><given-names>M</given-names></name><name><surname>Hopkinson</surname><given-names>DA</given-names></name><name><surname>Whitehouse</surname><given-names>DB</given-names></name><name><surname>Edwards</surname><given-names>YH</given-names></name></person-group>. <article-title>Phosphoglucomutase 1: a gene with two promoters and a duplicated first exon</article-title>. <source/>Biochem J. (<year>1993</year>) <volume>296</volume>(<issue>Pt 2</issue>):<fpage>417</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1042/bj2960417</pub-id><pub-id pub-id-type="pmid">8257433</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stojkovic</surname><given-names>T</given-names></name><name><surname>Vissing</surname><given-names>J</given-names></name><name><surname>Petit</surname><given-names>F</given-names></name><name><surname>Piraud</surname><given-names>M</given-names></name><name><surname>Orngreen</surname><given-names>MC</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Muscle glycogenosis due to phosphoglucomutase 1 deficiency</article-title>. <source/>N Engl J Med. (<year>2009</year>) <volume>361</volume>:<fpage>425</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc0901158</pub-id><pub-id pub-id-type="pmid">19625727</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tegtmeyer</surname><given-names>LC</given-names></name><name><surname>Rust</surname><given-names>S</given-names></name><name><surname>van Scherpenzeel</surname><given-names>M</given-names></name><name><surname>Ng</surname><given-names>BG</given-names></name><name><surname>Losfeld</surname><given-names>ME</given-names></name><name><surname>Timal</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Multiple phenotypes in phosphoglucomutase 1 deficiency</article-title>. <source/>N Engl J Med. (<year>2014</year>) <volume>370</volume>:<fpage>533</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1206605</pub-id><pub-id pub-id-type="pmid">24499211</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timal</surname><given-names>S</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Lehle</surname><given-names>L</given-names></name><name><surname>Adamowicz</surname><given-names>M</given-names></name><name><surname>Huijben</surname><given-names>K</given-names></name><name><surname>Sykut-Cegielska</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing</article-title>. <source/>Hum Mol Genet. (<year>2012</year>) <volume>21</volume>:<fpage>4151</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/dds123</pub-id><pub-id pub-id-type="pmid">22492991</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>B</given-names></name><name><surname>Medrano</surname><given-names>C</given-names></name><name><surname>Ecay</surname><given-names>MJ</given-names></name><name><surname>Ruiz-Sala</surname><given-names>P</given-names></name><name><surname>Martínez-Pardo</surname><given-names>M</given-names></name><name><surname>Ugarte</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene</article-title>. <source/>J Inherit Metab Dis. (<year>2013</year>) <volume>36</volume>:<fpage>535</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-012-9525-7</pub-id><pub-id pub-id-type="pmid">22976764</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>AM LC</given-names></name><name><surname>Freeze</surname><given-names>HH</given-names></name><name><surname>Ficicioglu</surname><given-names>C</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name></person-group>
<article-title>Hypoglycemia due to lower threshold of glucose-stimulated insulin secretion in phosphoglucomutase 1 deficiency</article-title>. In: <source/>Platform Presentation at: Annual Meeting of the Pediatric Academic Societies, April
<volume>25</volume>–<lpage>28</lpage>. <publisher-loc>San Diego, CA</publisher-loc> (<year>2015</year>).</mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrapers</surname><given-names>E</given-names></name><name><surname>Tegtmeyer</surname><given-names>LC</given-names></name><name><surname>Simic-Schleicher</surname><given-names>G</given-names></name><name><surname>Debus</surname><given-names>V</given-names></name><name><surname>Reunert</surname><given-names>J</given-names></name><name><surname>Balbach</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>News on Clinical details and treatment in PGM1-CDG</article-title>. <source/>JIMD Rep. (<year>2016</year>) <volume>26</volume>:<fpage>77</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1007/8904_2015_471</pub-id><pub-id pub-id-type="pmid">26303607</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group>. <article-title>Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study</article-title>. <source/>Sci Rep. (<year>2015</year>) <volume>5</volume>:<fpage>8926</fpage>. <pub-id pub-id-type="doi">10.1038/srep08926</pub-id><pub-id pub-id-type="pmid">25748215</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeken</surname><given-names>J</given-names></name><name><surname>Carchon</surname><given-names>H</given-names></name><name><surname>Stibler</surname><given-names>H</given-names></name></person-group>. <article-title>The carbohydrate-deficient glycoprotein syndromes: pre-Golgi and Golgi disorders?</article-title>
<source/>Glycobiology (<year>1993</year>) <volume>3</volume>:<fpage>423</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/3.5.423</pub-id><pub-id pub-id-type="pmid">8286854</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthijs</surname><given-names>G</given-names></name><name><surname>Schollen</surname><given-names>E</given-names></name><name><surname>Pardon</surname><given-names>E</given-names></name><name><surname>Veiga-Da-Cunha</surname><given-names>M</given-names></name><name><surname>Jaeken</surname><given-names>J</given-names></name><name><surname>Cassiman</surname><given-names>JJ</given-names></name><etal></etal></person-group>. <article-title>Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)</article-title>. <source/>Nat Genet. (<year>1997</year>) <volume>16</volume>:<fpage>88</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1038/ng0597-88</pub-id><pub-id pub-id-type="pmid">9140401</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>S</given-names></name><name><surname>Schollen</surname><given-names>E</given-names></name><name><surname>Van Schaftingen</surname><given-names>E</given-names></name><name><surname>Jaeken</surname><given-names>J</given-names></name><name><surname>Matthijs</surname><given-names>G</given-names></name></person-group>. <article-title>High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency)</article-title>. <source/>Am J Hum Genet. (<year>2001</year>) <volume>68</volume>:<fpage>347</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1086/318199</pub-id><pub-id pub-id-type="pmid">11156536</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthijs</surname><given-names>G</given-names></name><name><surname>Schollen</surname><given-names>E</given-names></name><name><surname>Heykants</surname><given-names>L</given-names></name><name><surname>Grunewald</surname><given-names>S</given-names></name></person-group>. <article-title>Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia)</article-title>. <source/>Mol Gen Metab. (<year>1999</year>) <volume>68</volume>:<fpage>220</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1006/mgme.1999.2914</pub-id><pub-id pub-id-type="pmid">10527672</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanti</surname><given-names>B</given-names></name><name><surname>Silink</surname><given-names>M</given-names></name><name><surname>Bhattacharya</surname><given-names>K</given-names></name><name><surname>Howard</surname><given-names>NJ</given-names></name><name><surname>Carpenter</surname><given-names>K</given-names></name><name><surname>Fietz</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Congenital disorder of glycosylation type Ia: heterogeneity in the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency</article-title>. <source/>J Inh Metab Dis. (<year>2009</year>) <volume>32</volume>:<fpage>S241</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-009-1180-2</pub-id><pub-id pub-id-type="pmid">19396570</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas</surname><given-names>OR</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Stanescu</surname><given-names>H</given-names></name><name><surname>García-Martínez</surname><given-names>E</given-names></name><name><surname>Caswell</surname><given-names>R</given-names></name><name><surname>Lango-Allen</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2</article-title>. <source/>J Am Soc Nephrol. (<year>2017</year>) <volume>28</volume>:<fpage>2529</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2016121312</pub-id><pub-id pub-id-type="pmid">28373276</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Flaschen</surname><given-names>RC</given-names></name><name><surname>Fulmer</surname><given-names>JT</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name><etal></etal></person-group>. <article-title>The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion</article-title>. <source/>J Clin Invest. (<year>2005</year>) <volume>115</volume>:<fpage>1006</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1172/JCI200522365</pub-id><pub-id pub-id-type="pmid">15761495</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odom</surname><given-names>DT</given-names></name><name><surname>Zizlsperger</surname><given-names>N</given-names></name><name><surname>Gordon</surname><given-names>DB</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Rinaldi</surname><given-names>NJ</given-names></name><name><surname>Murray</surname><given-names>HL</given-names></name><etal></etal></person-group>. <article-title>Control of pancreas and liver gene expression by HNF transcription factors</article-title>. <source/>Science (<year>2004</year>) <volume>303</volume>:<fpage>1378</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.1089769</pub-id><pub-id pub-id-type="pmid">14988562</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>A</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Kakei</surname><given-names>M</given-names></name><name><surname>Hatakeyama</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Fukui</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells</article-title>. <source/>J Biol Chem. (<year>2006</year>) <volume>281</volume>:<fpage>5246</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M507496200</pub-id><pub-id pub-id-type="pmid">16377800</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>ER</given-names></name><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Steele</surname><given-names>AM</given-names></name><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Stals</surname><given-names>K</given-names></name><name><surname>Shield</surname><given-names>JP</given-names></name><etal></etal></person-group>. <article-title>Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene</article-title>. <source/>PLoS Med. (<year>2007</year>) <volume>4</volume>:<fpage>e118</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0040118</pub-id><pub-id pub-id-type="pmid">17407387</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>H</given-names></name><name><surname>Oda</surname><given-names>N</given-names></name><name><surname>Kaisaki</surname><given-names>PJ</given-names></name><name><surname>Menzel</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><etal></etal></person-group>. <article-title>Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)</article-title>. <source/>Nature (<year>1996</year>) <volume>384</volume>:<fpage>458</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/384458a0</pub-id><pub-id pub-id-type="pmid">8945471</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Oda</surname><given-names>N</given-names></name><name><surname>Kaisaki</surname><given-names>PJ</given-names></name><name><surname>Menzel</surname><given-names>S</given-names></name><name><surname>Furuta</surname><given-names>H</given-names></name><name><surname>Vaxillaire</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)</article-title>. <source/>Nature (<year>1996</year>) <volume>384</volume>:<fpage>455</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/384455a0</pub-id><pub-id pub-id-type="pmid">8945470</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>VB</given-names></name><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Senniappan</surname><given-names>S</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response</article-title>. <source/>Diab Med. (<year>2014</year>) <volume>31</volume>:<fpage>e11</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/dme.12369</pub-id><pub-id pub-id-type="pmid">24299156</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajans</surname><given-names>SS</given-names></name><name><surname>Bell</surname><given-names>GI</given-names></name></person-group>. <article-title>Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4alpha (HNF4A)</article-title>. <source/>Diabetologia (<year>2007</year>) <volume>50</volume>:<fpage>2600</fpage>–<lpage>01</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-007-0833-7</pub-id><pub-id pub-id-type="pmid">17891372</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Mali</surname><given-names>G</given-names></name><name><surname>Cody</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Schwahn</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations</article-title>. <source/>Eur J Endocrinol. (<year>2010</year>) <volume>162</volume>:<fpage>987</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-09-0861</pub-id><pub-id pub-id-type="pmid">20164212</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>RR</given-names></name><name><surname>Locke</surname><given-names>J</given-names></name><name><surname>Colclough</surname><given-names>K</given-names></name><name><surname>Wales</surname><given-names>J</given-names></name><name><surname>Conn</surname><given-names>JJ</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><etal></etal></person-group>. <article-title>Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations</article-title>. <source/>Diabetes (<year>2008</year>) <volume>57</volume>:<fpage>1659</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.2337/db07-1657</pub-id><pub-id pub-id-type="pmid">18268044</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanik</surname><given-names>J</given-names></name><name><surname>Skopkova</surname><given-names>M</given-names></name><name><surname>Brennerova</surname><given-names>K</given-names></name><name><surname>Danis</surname><given-names>D</given-names></name><name><surname>Rosolankova</surname><given-names>M</given-names></name><name><surname>Salingova</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Congenital hyperinsulinism and glycogenosis-like phenotype due to a novel HNF4A mutation</article-title>. <source/>Diabetes Res Clin Pract. (<year>2017</year>) <volume>126</volume>:<fpage>144</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2017.02.014</pub-id><pub-id pub-id-type="pmid">28242437</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanescu</surname><given-names>DE</given-names></name><name><surname>Hughes</surname><given-names>N</given-names></name><name><surname>Kaplan</surname><given-names>B</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>De Leon</surname><given-names>DD</given-names></name></person-group>. <article-title>Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A</article-title>. <source/>J Clin Endocrinol Metab. (<year>2012</year>) <volume>97</volume>:<fpage>E2026</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2012-1356</pub-id><pub-id pub-id-type="pmid">22802087</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenkova</surname><given-names>K</given-names></name><name><surname>Malikova</surname><given-names>J</given-names></name><name><surname>Nessa</surname><given-names>A</given-names></name><name><surname>Dusatkova</surname><given-names>L</given-names></name><name><surname>Bjørkhaug</surname><given-names>L</given-names></name><name><surname>Obermannova</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>High incidence of heterozygous ABCC8 and HNF1A mutations in Czech patients with congenital hyperinsulinism</article-title>. <source/>J Clin Endocrinol Metab. (<year>2015</year>) <volume>100</volume>:<fpage>E1540</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2015-2763</pub-id><pub-id pub-id-type="pmid">26431509</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>LeLay</surname><given-names>J</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Rieck</surname><given-names>S</given-names></name><name><surname>Friedman</surname><given-names>JR</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group>. <article-title>Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development</article-title>. <source/>Genes Dev. (<year>2008</year>) <volume>22</volume>:<fpage>3435</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1752608</pub-id><pub-id pub-id-type="pmid">19141476</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>D</given-names></name><name><surname>Vignola</surname><given-names>ML</given-names></name><name><surname>Gualtieri</surname><given-names>A</given-names></name><name><surname>Scagliotti</surname><given-names>V</given-names></name><name><surname>McNamara</surname><given-names>P</given-names></name><name><surname>Peak</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Novel FOXA2 mutation causes hyperinsulinism, hypopituitarism with craniofacial and endoderm-derived organ abnormalities</article-title>. <source/>Hum Mol Genet. (<year>2017</year>) <volume>26</volume>:<fpage>4315</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddx318</pub-id><pub-id pub-id-type="pmid">28973288</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Sund</surname><given-names>NJ</given-names></name><name><surname>Behr</surname><given-names>R</given-names></name><name><surname>Herrera</surname><given-names>PL</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group>. <article-title>Foxa2 is required for the differentiation of pancreatic alpha-cells</article-title>. <source/>Dev Biol. (<year>2005</year>) <volume>278</volume>:<fpage>484</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2004.10.012</pub-id><pub-id pub-id-type="pmid">15680365</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Sund</surname><given-names>NJ</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name><name><surname>Stoffers</surname><given-names>DA</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name></person-group>. <article-title>Foxa2 controls Pdx1 gene expression in pancreatic beta-cells <italic>in vivo</italic></article-title>. <source/>Diabetes (<year>2002</year>) <volume>51</volume>:<fpage>2546</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.51.8.2546</pub-id><pub-id pub-id-type="pmid">12145169</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vajravelu</surname><given-names>ME</given-names></name><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Krock</surname><given-names>B</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Langdon</surname><given-names>D</given-names></name><name><surname>Alter</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Congenital hyperinsulinism and hypopituitarism attributable to a novel mutation in FOXA2</article-title>. <source/>J Clin Endocrinol Metab. (<year>2018</year>) <volume>103</volume>:<fpage>1042</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2017-02157</pub-id><pub-id pub-id-type="pmid">29329447</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Fei</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name></person-group>. <article-title>Conditional tissue-specific Foxa2 ablation in mouse pancreas causes hyperinsulinemic hypoglycemia</article-title>. <source/>Am J Ther. (<year>2016</year>) <volume>23</volume>:<fpage>e1442</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/MJT.0000000000000399</pub-id><pub-id pub-id-type="pmid">26882312</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sund</surname><given-names>NJ</given-names></name><name><surname>Vatamaniuk</surname><given-names>MZ</given-names></name><name><surname>Casey</surname><given-names>M</given-names></name><name><surname>Ang</surname><given-names>SL</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Stoffers</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia</article-title>. <source/>Genes Dev. (<year>2001</year>) <volume>15</volume>:<fpage>1706</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1101/gad.901601</pub-id><pub-id pub-id-type="pmid">11445544</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayem-Quere</surname><given-names>M</given-names></name><name><surname>Giuliano</surname><given-names>F</given-names></name><name><surname>Wagner-Mahler</surname><given-names>K</given-names></name><name><surname>Massol</surname><given-names>C</given-names></name><name><surname>Crouzet-Ozenda</surname><given-names>L</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>Delineation of a region responsible for panhypopituitarism in 20p11.2</article-title>. <source/>Am J Med Genet Part A (<year>2013</year>) <volume>161a</volume>:<fpage>1547</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.35921</pub-id><pub-id pub-id-type="pmid">23657910</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>PG</given-names></name><name><surname>Wetherbee</surname><given-names>JJ</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Hersh</surname><given-names>JH</given-names></name></person-group>. <article-title>20p11 deletion in a female child with panhypopituitarism, cleft lip and palate, dysmorphic facial features, global developmental delay and seizure disorder</article-title>. <source/>Am J Med Genet Part A (<year>2011</year>) <volume>155a</volume>:<fpage>186</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.33763</pub-id><pub-id pub-id-type="pmid">21204230</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Cosgrove</surname><given-names>KE</given-names></name><name><surname>Shepherd</surname><given-names>RM</given-names></name><name><surname>Luharia</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>VV</given-names></name><name><surname>Kassem</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphate-sensitive potassium channels</article-title>. <source/>J Clin Endocrinol Metab. (<year>2005</year>) <volume>90</volume>:<fpage>4376</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-0158</pub-id><pub-id pub-id-type="pmid">15811927</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>T</given-names></name><name><surname>Ihara</surname><given-names>K</given-names></name><name><surname>Ochiai</surname><given-names>M</given-names></name><name><surname>Kinjo</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Kojima-Ishii</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycemia of infancy in Sotos syndrome</article-title>. <source/>Am J Med Genet A (<year>2013</year>) <volume>161A</volume>:<fpage>34</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.35657</pub-id><pub-id pub-id-type="pmid">23239432</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terespolsky</surname><given-names>D</given-names></name><name><surname>Farrell</surname><given-names>SA</given-names></name><name><surname>Siegel-Bartelt</surname><given-names>J</given-names></name><name><surname>Weksberg</surname><given-names>R</given-names></name></person-group>. <article-title>Infantile lethal variant of Simpson-Golabi-Behmel syndrome associated with hydrops fetalis</article-title>. <source/>Am J Med Genet. (<year>1995</year>) <volume>59</volume>:<fpage>329</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320590310</pub-id><pub-id pub-id-type="pmid">8599356</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Güemes</surname><given-names>M</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Hyperinsulinemic hypoglycemia</article-title>. <source/>Pediatr Clin North Am. (<year>2015</year>) <volume>62</volume>:<fpage>1017</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcl.2015.04.010</pub-id><pub-id pub-id-type="pmid">26210630</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhayyat</surname><given-names>H</given-names></name><name><surname>Christesen</surname><given-names>HB</given-names></name><name><surname>Steer</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>H</given-names></name><name><surname>Brusgaard</surname><given-names>K</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Mosaic Turner syndrome and hyperinsulinaemic hypoglycaemia</article-title>. <source/>J Pediatr Endocrinol Metab. (<year>2006</year>) <volume>19</volume>:<fpage>1451</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1515/JPEM.2006.19.12.1451</pub-id><pub-id pub-id-type="pmid">17252699</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamame</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>N</given-names></name><name><surname>Homma</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Inokuchi</surname><given-names>M</given-names></name><name><surname>Kosaki</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycemia in a newborn infant with trisomy 13</article-title>. <source/>Am J Med Genet A (<year>2004</year>) <volume>129A</volume>:<fpage>321</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.30147</pub-id><pub-id pub-id-type="pmid">15326637</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbarayan</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>Hypoglycemia in Kabuki syndrome</article-title>. <source/>Am J Med Genet A (<year>2014</year>) <volume>164A</volume>:<fpage>467</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36256</pub-id><pub-id pub-id-type="pmid">24311525</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>S</given-names></name><name><surname>Ramadan</surname><given-names>D</given-names></name><name><surname>Alkhayyat</surname><given-names>H</given-names></name><name><surname>Al-Sharkawi</surname><given-names>I</given-names></name><name><surname>Backer</surname><given-names>KC</given-names></name><name><surname>El-Sabban</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Costello syndrome and hyperinsulinemic hypoglycemia</article-title>. <source/>Am J Med Genet A (<year>2005</year>) <volume>139</volume>:<fpage>227</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.31011</pub-id><pub-id pub-id-type="pmid">16278907</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Mutair</surname><given-names>AN</given-names></name><name><surname>Brusgaard</surname><given-names>K</given-names></name><name><surname>Bin-Abbas</surname><given-names>B</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Felimban</surname><given-names>N</given-names></name><name><surname>Al Shaikh</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Heterogeneity in phenotype of usher-congenital hyperinsulinism syndrome: hearing loss, retinitis pigmentosa, and hyperinsulinemic hypoglycemia ranging from severe to mild with conversion to diabetes</article-title>. <source/>Diabetes Care (<year>2013</year>) <volume>36</volume>:<fpage>557</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.2337/dc12-1174</pub-id><pub-id pub-id-type="pmid">23150283</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splawski</surname><given-names>I</given-names></name><name><surname>Timothy</surname><given-names>KW</given-names></name><name><surname>Sharpe</surname><given-names>LM</given-names></name><name><surname>Decher</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Bloise</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Ca(V)1</article-title>.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. <source/>Cell (<year>2004</year>) <volume>119</volume>:<fpage>19</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2004.09.011</pub-id><pub-id pub-id-type="pmid">15454078</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lonlay</surname><given-names>P</given-names></name><name><surname>Cuer</surname><given-names>M</given-names></name><name><surname>Vuillaumier-Barrot</surname><given-names>S</given-names></name><name><surname>Beaune</surname><given-names>G</given-names></name><name><surname>Castelnau</surname><given-names>P</given-names></name><name><surname>Kretz</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: a new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose</article-title>. <source/>J Pediatr. (<year>1999</year>) <volume>135</volume>:<fpage>379</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-3476(99)70139-3</pub-id><pub-id pub-id-type="pmid">10484808</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Eklund</surname><given-names>EA</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Freeze</surname><given-names>HH</given-names></name></person-group>. <article-title>Congenital disorder of glycosylation Id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia</article-title>. <source/>J Clin Endocrinol Metab. (<year>2005</year>) <volume>90</volume>:<fpage>4371</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2005-0250</pub-id><pub-id pub-id-type="pmid">15840742</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>MI</given-names></name><name><surname>Scarani</surname><given-names>R</given-names></name><name><surname>Po</surname><given-names>C</given-names></name><name><surname>Agosto</surname><given-names>C</given-names></name><name><surname>Ottonello</surname><given-names>G</given-names></name><name><surname>Benini</surname><given-names>F</given-names></name></person-group>. <article-title>Congenital central hypoventilation syndrome and hypoglycaemia</article-title>. <source/>Acta Paediatr. (<year>2012</year>) <volume>101</volume>:<fpage>e92</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.2011.02533.x</pub-id><pub-id pub-id-type="pmid">22103583</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>U</given-names></name><name><surname>Preece</surname><given-names>MA</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>DA</given-names></name><name><surname>McKiernan</surname><given-names>PJ</given-names></name></person-group>. <article-title>Hyperinsulinism in tyrosinaemia type I</article-title>. <source/>J Inherit Metab Dis. (<year>2005</year>) <volume>28</volume>:<fpage>131</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-005-5517-1</pub-id><pub-id pub-id-type="pmid">15877201</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>D</given-names></name><name><surname>Patil</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>R</given-names></name><name><surname>Didi</surname><given-names>M</given-names></name><name><surname>Senniappan</surname><given-names>S</given-names></name></person-group>. <article-title>Congenital hyperinsulinism and Poland syndrome in association with 10p13–14 duplication</article-title>. <source/>Endocrinol Diabetes Metab Case Rep. (<year>2017</year>). <pub-id pub-id-type="doi">10.1530/EDM-16-0125</pub-id> [Epub ahead of print].<pub-id pub-id-type="pmid">28458900</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Itonaga</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Fukami</surname><given-names>M</given-names></name><name><surname>Yorifuji</surname><given-names>T</given-names></name><name><surname>Ihara</surname><given-names>K</given-names></name></person-group>. <article-title>A case of CHARGE syndrome associated with hyperinsulinemic hypoglycemia in infancy</article-title>. <source/>Eur J Med Genet. (<year>2018</year>) <volume>61</volume>:<fpage>312</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmg.2018.01.008</pub-id><pub-id pub-id-type="pmid">29355723</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shuman</surname><given-names>C</given-names></name><name><surname>Beckwith</surname><given-names>JB</given-names></name><name><surname>Weksberg</surname><given-names>R</given-names></name></person-group>
<article-title>Beckwith-Wiedemann Syndrome</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>Source GeneReviews<sup>®;</sup> [Internet]. <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; <year>1993-2018</year> (<year>2000</year>) (Accessed August 11, 2016).</mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBaun</surname><given-names>MR</given-names></name><name><surname>King</surname><given-names>AA</given-names></name><name><surname>White</surname><given-names>N</given-names></name></person-group>. <article-title>Hypoglycemia in Beckwith-Wiedemann syndrome</article-title>. <source/>Semin Perinatol. (<year>2000</year>) <volume>24</volume>:<fpage>164</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1053/sp.2000.6366</pub-id><pub-id pub-id-type="pmid">10805171</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Shuman</surname><given-names>C</given-names></name><name><surname>Chitayat</surname><given-names>D</given-names></name><name><surname>Steele</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>PN</given-names></name><name><surname>Bourgeois</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Severe presentation of Beckwith-Wiedemann syndrome associated with high levels of constitutional paternal uniparental disomy for chromosome 11p15</article-title>. <source/>Am J Med Genet A. (<year>2007</year>) <volume>143A</volume>:<fpage>3010</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.32030</pub-id><pub-id pub-id-type="pmid">18000906</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senniappan</surname><given-names>S</given-names></name><name><surname>Ismail</surname><given-names>D</given-names></name><name><surname>Shipster</surname><given-names>C</given-names></name><name><surname>Beesley</surname><given-names>C</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name></person-group>. <article-title>The heterogeneity of hyperinsulinaemic hypoglycaemia in 19 patients with Beckwith-Wiedemann syndrome due to KvDMR1 hypomethylation</article-title>. <source/>J Pediatr Endocrinol Metab. (<year>2015</year>) <volume>28</volume>:<fpage>83</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2013-0390</pub-id><pub-id pub-id-type="pmid">24468603</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>I</given-names></name><name><surname>Higashimoto</surname><given-names>K</given-names></name><name><surname>Tsuchida</surname><given-names>S</given-names></name><name><surname>Noguchi</surname><given-names>A</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Congenital hyperinsulinism in an infant with paternal uniparental disomy on chromosome 11p15: few clinical features suggestive of Beckwith-Wiedemann syndrome</article-title>. <source/>Endocr J. (<year>2013</year>) <volume>60</volume>:<fpage>403</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1507/endocrj.EJ12-0242</pub-id><pub-id pub-id-type="pmid">23197114</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohda</surname><given-names>Y</given-names></name><name><surname>Oka</surname><given-names>S</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Yoshiura</surname><given-names>K</given-names></name><name><surname>Kondoh</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Neonatal case of novel KMT2D mutation in Kabuki syndrome with severe hypoglycemia</article-title>. <source/>Pediatr Int. (<year>2015</year>) <volume>57</volume>:<fpage>726</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/ped.12574</pub-id><pub-id pub-id-type="pmid">25944076</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>N</given-names></name><name><surname>Ihara</surname><given-names>K</given-names></name><name><surname>Kojima-Ishii</surname><given-names>K</given-names></name><name><surname>Ochiai</surname><given-names>M</given-names></name><name><surname>Ohkubo</surname><given-names>K</given-names></name><name><surname>Kawamoto</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann, Sotos, and Kabuki syndromes: a nationwide survey in Japan</article-title>. <source/>Am J Med Genet A (<year>2017</year>) <volume>173</volume>:<fpage>360</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.38011</pub-id><pub-id pub-id-type="pmid">28102591</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>KL</given-names></name><name><surname>Johnson</surname><given-names>AEK</given-names></name><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Kandikatla</surname><given-names>P</given-names></name><name><surname>Deml</surname><given-names>J</given-names></name><name><surname>Nelakuditi</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Congenital hyperinsulinism as the presenting feature of Kabuki syndrome: clinical and molecular characterization of 10 affected individuals</article-title>. <source/>GenetMed. (<year>2019</year>) <volume>21</volume>:<fpage>233</fpage>–<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1038/s41436-018-0013-9</pub-id><pub-id pub-id-type="pmid">30097611</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Takagi</surname><given-names>M</given-names></name><name><surname>Yoshihashi</surname><given-names>H</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Narumi</surname><given-names>S</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>A case with neonatal hyperinsulinemic hypoglycemia: It is a characteristic complication of Sotos syndrome</article-title>. <source/>Am J Med Genet A (<year>2015</year>) <volume>167A</volume>:<fpage>1171</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36996</pub-id><pub-id pub-id-type="pmid">25712828</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Boer</surname><given-names>L</given-names></name><name><surname>Van Duyvenvoorde</surname><given-names>HA</given-names></name><name><surname>Willemstein-Van Hove</surname><given-names>EC</given-names></name><name><surname>Hoogerbrugge</surname><given-names>CM</given-names></name><name><surname>Van Doorn</surname><given-names>J</given-names></name><name><surname>Maassen</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF system</article-title>. <source/>Eur J Endocrinol. (<year>2004</year>) <volume>151</volume>:<fpage>333</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1530/eje.0.1510333</pub-id><pub-id pub-id-type="pmid">15362962</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappella</surname><given-names>M</given-names></name><name><surname>Graziani</surname><given-names>V</given-names></name><name><surname>Pragliola</surname><given-names>A</given-names></name><name><surname>Sensi</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Muratori</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Hyperinsulinemic hypoglycaemia in a Turner syndrome with ring (X)</article-title>. <source/>Case Rep Pediatr. (<year>2015</year>) <volume>2015</volume>:<fpage>561974</fpage>. <pub-id pub-id-type="doi">10.1155/2015/561974</pub-id><pub-id pub-id-type="pmid">26064751</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietzner</surname><given-names>V</given-names></name><name><surname>Weigel</surname><given-names>JF</given-names></name><name><surname>Wand</surname><given-names>D</given-names></name><name><surname>Merkenschlager</surname><given-names>A</given-names></name><name><surname>Bernhard</surname><given-names>MK</given-names></name></person-group>. <article-title>Low-level hyperinsulinism with hypoglycemic spells in an infant with mosaic Turner syndrome and mild Kabuki-like phenotype: a case report and review of the literature</article-title>. <source/>J Pediatr Endocrinol Metab. (<year>2014</year>) <volume>27</volume>:<fpage>165</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2013-0090</pub-id><pub-id pub-id-type="pmid">23950569</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>CE</given-names></name><name><surname>Boodhansingh</surname><given-names>KE</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Conlin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>SA</given-names></name><etal></etal></person-group>
<article-title>Congenital hyperinsulinism in infants with Turner syndrome: possible association with monosomy X and KDM6A haploinsufficiency</article-title>. <source/>Horm Res Paediatr. (<year>2018</year>) <volume>14</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1159/000488347</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>